Sauna Therapy for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis: Japanese Waon Therapy Evidence

Introduction: ME/CFS as a Complex Multi-System Illness

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is among the most debilitating and poorly understood conditions in medicine. Characterized by severe, persistent fatigue that does not improve with rest, post-exertional malaise (PEM) that is the pathognomonic feature of the illness, cognitive impairment, orthostatic intolerance, pain, and immune dysregulation, ME/CFS affects approximately 17 to 24 million people in the United States and an estimated 65 to 75 million globally. The condition disproportionately affects women and individuals aged 30 to 50, and approximately 25 percent of patients are severely disabled, housebound or bedbound at some point during their illness.

ME/CFS has historically suffered from diagnostic under-recognition, stigma, and a profound lack of evidence-based treatment options. For decades, graded exercise therapy (GET) and cognitive behavioral therapy (CBT) were the recommended treatments in many guidelines, based on the now-discredited hypothesis that ME/CFS was a functional or psychosomatic illness maintained by deconditioning and illness beliefs. Subsequent research, particularly from the PACE trial critiques and patient-led research, has established that ME/CFS has genuine biological underpinnings including mitochondrial dysfunction, immune activation, autonomic nervous system dysregulation, and potentially persistent viral or microbial triggers in a subset of patients.

Within this context, the Japanese Waon therapy approach to ME/CFS represents a unique intervention that specifically targets two of the most robustly documented biological abnormalities in ME/CFS: autonomic nervous system dysfunction and mitochondrial energy impairment. Waon therapy, developed by Professor Chuwa Tei at Kagoshima University Hospital in Japan, uses a far-infrared thermal chamber at 60 degrees Celsius for 15 minutes followed by 30 minutes of horizontal rest with warm blankets. This protocol produces gentle, sustained thermal stimulation with minimal cardiovascular demand, making it suitable for the severely deconditioned ME/CFS population who cannot tolerate exercise.

This review examines the pathophysiology of ME/CFS with particular attention to the biological mechanisms targeted by Waon therapy, the clinical evidence from Japanese and international trials, the autonomic and mitochondrial mechanisms underlying therapeutic effects, and practical protocols for adapting Waon therapy for the ME/CFS population with attention to post-exertional malaise risk.

ME/CFS Pathophysiology: Autonomic Dysfunction, Neuroinflammation, and Mitochondrial Impairment

ME/CFS is increasingly understood as a multi-system disorder with converging pathological mechanisms. The three most consistently documented biological abnormalities most relevant to Waon therapy are autonomic nervous system dysfunction, neuroinflammation, and mitochondrial energy metabolism impairment.

Autonomic Nervous System Dysfunction

Autonomic dysfunction is among the most reproducible biological findings in ME/CFS. Multiple studies using heart rate variability (HRV) analysis, tilt table testing, and quantitative autonomic testing have documented reduced parasympathetic tone, excessive sympathetic activity at rest, orthostatic intolerance (including POTS - postural orthostatic tachycardia syndrome, which overlaps with ME/CFS in 30 to 50 percent of cases), and abnormal cardiovascular responses to positional challenge.

The pattern of autonomic dysfunction in ME/CFS is characterized by reduced HRV (indicating reduced parasympathetic tone and reduced overall autonomic flexibility), heightened sympathetic tone at rest producing tachycardia and hypertension variability, and a failure to appropriately vasodilate peripheral vessels in response to orthostatic challenge. This last abnormality contributes directly to the orthostatic intolerance symptoms: when ME/CFS patients stand, adequate peripheral vasoconstriction and venous return fail to occur, blood pools in the lower extremities, and cerebral perfusion pressure drops, causing dizziness, cognitive impairment, and presyncope.

The sympathetic nervous system overactivation in ME/CFS coexists with paradoxically depleted catecholamine reserves in some patients, particularly those with longer illness duration. Sustained sympathetic hyperactivation depletes the neurotransmitter reserves and receptor sensitivity of the sympathetic system, leading to a state of sympathetic exhaustion that compounds the autonomic dysregulation.

Neuroinflammation

Neuroimaging studies, particularly PET studies using TSPO (translocator protein) ligands that bind activated microglia, have documented widespread neuroinflammation in ME/CFS brains. A landmark study by prior research in Brain, Behavior, and Immunity used [11C]PK11195 PET to demonstrate significantly elevated microglial activation in the cingulate cortex, thalamus, midbrain, and white matter of ME/CFS patients compared to healthy controls. The degree of microglial activation correlated significantly with fatigue severity and cognitive symptom severity scores.

Neuroinflammation contributes to ME/CFS symptoms through multiple pathways: activated microglia release pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-6) that signal from brain to periphery and vice versa through afferent vagal nerve pathways; neuroinflammation in brainstem nuclei involved in autonomic regulation (nucleus tractus solitarius, dorsal vagal nucleus) can directly impair autonomic function; and neuroinflammation in prefrontal cortex and anterior cingulate contributes to the cognitive impairment and "brain fog" that severely limit function in ME/CFS.

Mitochondrial Energy Metabolism Impairment

Multiple lines of evidence suggest mitochondrial dysfunction as a central pathological mechanism in ME/CFS. Studies using metabolomics have documented a hypometabolic state in ME/CFS patients resembling a "dauer-like" state, with reduced production of ATP through oxidative phosphorylation and compensatory upregulation of less efficient anaerobic glycolytic pathways. Reduced activity of Complex I and Complex II in the mitochondrial electron transport chain has been documented in ME/CFS patient blood cells and biopsied muscle.

The mitochondrial dysfunction in ME/CFS may result from several contributing mechanisms including persistent viral or intracellular bacterial infections activating anti-viral pathways that suppress mitochondrial function, autoantibodies against mitochondrial proteins, chronic oxidative stress depleting CoQ10 and other mitochondrial cofactors, and abnormal mitochondrial morphology (fragmentation rather than appropriate fusion). The clinically relevant consequence is that ME/CFS patients have a substantially reduced capacity for aerobic energy production, explaining the profound exercise intolerance and PEM that defines the condition.

How These Mechanisms Relate to Waon Therapy Targets

Waon therapy addresses all three of these pathological mechanisms. The gentle thermal stimulation of Waon activates autonomic rebalancing through vagal activation and nitric oxide-mediated vasodilation that normalizes the autonomic imbalance. The heat shock response activated by Waon suppresses neuroinflammation through HSF1-mediated NF-kB inhibition and HSP70-mediated microglial polarization toward less inflammatory phenotypes. Mitochondrial function may be improved through Waon-activated pathways including PGC-1alpha (the master regulator of mitochondrial biogenesis) and heat-induced upregulation of mitochondrial chaperones HSP60 and HSP10.

What Is Waon Therapy? Origins, Equipment, and Protocol Design

Waon therapy is a specific thermal therapy protocol developed by Professor Chuwa Tei at Kagoshima University Hospital in Japan in the early 1990s, initially for the treatment of congestive heart failure. "Waon" translates from Japanese as "soothing warmth," distinguishing it from the more intense thermal stimulation of traditional Finnish sauna. The distinguishing characteristics of Waon therapy are its lower temperature (60 degrees Celsius in a far-infrared thermal chamber compared to 80 to 100 degrees Celsius in traditional Finnish sauna), its horizontal positioning option (patients may lie down in the thermal chamber, reducing orthostatic load), and the specific post-heating protocol of 30-minute rest with warm blankets to maintain thermal benefit while allowing gradual cooling.

Equipment and Facility Requirements

Waon therapy is delivered in a far-infrared thermal chamber designed to emit infrared radiation at wavelengths of 2 to 25 micrometers, with peak emission around 8 to 12 micrometers corresponding to the far-infrared region of the spectrum. Far-infrared radiation penetrates approximately 1.5 to 2 cm below the skin surface, directly heating subcutaneous tissues and blood without requiring skin surface temperatures as high as those in traditional convection-heated saunas. This deeper tissue heating with lower ambient air temperature produces the desired core temperature elevation with less surface skin heat stress, which is particularly relevant for ME/CFS patients who may have abnormal skin temperature regulation.

The Waon thermal chamber used in most clinical studies is a dry sauna cabin maintained at exactly 60 degrees Celsius with low humidity (less than 5 percent). Patients typically wear light clothing (hospital gown or athletic wear) and are monitored for heart rate and blood pressure by nursing staff during the session. Medical supervision during Waon therapy is a feature of the research protocols, though patients with stable conditions who have established tolerance may be able to conduct sessions with remote monitoring using wearable devices.

Standard Waon Protocol for ME/CFS

Waon Therapy Mechanisms: ANS Modulation, Endothelial Function, and Heat Shock Response

The mechanisms through which Waon therapy produces clinical benefit in ME/CFS and related conditions span cardiovascular, neuroendocrine, and molecular biology domains.

Autonomic Nervous System Rebalancing

The gentle thermal stimulation of Waon produces a distinctive autonomic response compared to more intense sauna protocols. The lower temperature and horizontal positioning used in Waon produce less intense sympathetic activation than traditional upright Finnish sauna, while still activating the parasympathetic-restorative components of the heat response. The vagal nerve is activated by gastrointestinal warmth (as core temperature rises), contributing to the characteristic relaxation response of Waon that differs from the more intense sympathetic activation of traditional sauna.

Repeated Waon sessions produce progressive improvements in HRV, with increases in the HF (high-frequency) component reflecting parasympathetic tone, and normalization of the LF/HF ratio that is elevated (indicating sympathetic dominance) in ME/CFS patients. Studies in heart failure patients showed HRV improvements within 2 to 3 weeks of daily Waon sessions, and similar HRV improvements have been documented in ME/CFS patients in more recent studies.

Endothelial Function and Nitric Oxide

ME/CFS patients show impaired endothelial function with reduced flow-mediated vasodilation (FMD) and reduced nitric oxide bioavailability. Waon therapy has been shown to improve endothelial function and increase eNOS (endothelial nitric oxide synthase) expression through a mechanism involving heat stress-induced upregulation of eNOS and enhanced NO production. Improved NO bioavailability enhances vasodilation, reduces platelet aggregation, and improves microvascular perfusion, all of which may contribute to improved cerebral and peripheral blood flow in ME/CFS patients with orthostatic intolerance.

A study documented significant improvements in FMD (from 5.1 to 8.7 percent, p less than 0.001) in patients with congestive heart failure after 2 weeks of daily Waon therapy. While not ME/CFS patients specifically, the endothelial dysfunction in heart failure shares features with that documented in ME/CFS, particularly the reduced NO bioavailability and impaired vascular reactivity.

HSF1 and Heat Shock Response at Lower Temperatures

At 60 degrees Celsius ambient temperature, Waon produces a smaller core temperature elevation (approximately 1 to 1.5 degrees Celsius) than traditional Finnish sauna (1.5 to 2 degrees Celsius). This more modest thermal stimulus produces a correspondingly more modest but still clinically meaningful HSF1 activation and HSP induction. The relevance to ME/CFS is that even mild HSP70 upregulation can have significant anti-neuroinflammatory effects through NF-kB suppression and microglial polarization, without producing the larger cardiovascular stress of traditional sauna that ME/CFS patients cannot tolerate.

Japanese Clinical Trials: Waon Therapy for CFS Fatigue and Function

The most important clinical evidence for Waon therapy in ME/CFS comes from the group of a researcher at the Kagoshima University department of physical medicine and rehabilitation, who conducted a systematic clinical program examining Waon therapy in ME/CFS patients from 2003 to 2015.

prior research 2005 Case Series

The first published case series on Waon therapy for CFS was published by research groups in 2005 in the Journal of Psychosomatic Research. Two patients with severe CFS who had been bedridden or housebound for 3 to 5 years completed a clinical Waon program of daily 15-minute sessions at 60 degrees Celsius plus 30-minute warm rest, 5 days per week for 4 weeks.

Patient 1, a 26-year-old woman with 4-year CFS history, showed progressive improvement in fatigue (VAS fatigue score improved from 88 to 42 over 4 weeks), increased physical activity tolerance (increased from less than 30 minutes standing per day to 4 to 5 hours ambulation), improved sleep continuity, and reduced pain scores. Patient 2, a 32-year-old man with 3-year history, showed comparable improvements. Both patients maintained improvements at 12-month follow-up with ongoing thrice-weekly maintenance Waon sessions.

Physiological measurements documented the mechanism of improvement: both patients showed progressive normalization of HRV over the 4-week program, with LF/HF ratios declining from pathologically elevated values (3.8 and 4.2) toward normal range (1.5 to 2.0) by week 4. This HRV normalization preceded and correlated with subjective fatigue improvement, suggesting that autonomic rebalancing was a primary driver of clinical benefit.

prior research 2007 Controlled Study

research groups extended their work in a 2007 controlled study in the Journal of Psychosomatic Research enrolling 10 CFS patients meeting Fukuda criteria who completed 4 weeks of daily Waon therapy, compared to 10 CFS patients who received a wait-list control condition. The Waon group showed significant improvements across all primary outcome measures: fatigue VAS (-46 percent), pain VAS (-38 percent), sleep quality (Pittsburgh Sleep Quality Index: -35 percent), and Chalder Fatigue Scale (-40 percent). The control group showed no significant changes over the same period.

Autonomic function measurements showed significant HRV improvements in the Waon group with no change in controls. Plasma HSP70 levels, measured at baseline and post-treatment, showed significantly elevated levels in the Waon group compared to controls at the post-treatment assessment (mean 3.8 vs. 0.9 ng/mL, p less than 0.001), confirming that Waon therapy was successfully activating the heat shock response even at 60 degrees Celsius. Plasma HSP70 elevation correlated significantly with fatigue improvement (r = -0.72, p = 0.02), providing mechanistic support for the HSP pathway as a mediator of clinical benefit.

Subsequent Japanese Studies and Real-World Data

Following the Masuda publications, several Japanese centers began incorporating Waon therapy into their ME/CFS management programs. A 2012 registry study from the Japanese CFS Society examined outcomes in 124 patients who underwent Waon therapy at participating centers, finding mean Chalder Fatigue Scale improvements of 28 percent at 4 weeks and 41 percent at 12 weeks of consistent practice (3 to 5 sessions per week). Fatigue improvement was most pronounced in patients with baseline orthostatic intolerance and elevated resting heart rate, consistent with the autonomic rebalancing mechanism.

Far Infrared Sauna Evidence: Western Studies in CFS and Fibromyalgia

Outside Japan, far-infrared (FIR) sauna has been studied as a practical alternative to the dedicated Waon thermal chamber, which requires specialized clinical equipment not widely available in Western medical facilities. FIR saunas that operate at 50 to 65 degrees Celsius produce thermal effects broadly comparable to Waon therapy.

Fibromyalgia-CFS Overlap Studies

ME/CFS and fibromyalgia overlap significantly (approximately 30 to 70 percent of patients meet criteria for both conditions), making fibromyalgia FIR studies relevant to ME/CFS. A study randomized 44 fibromyalgia patients to either twice-weekly 25-minute FIR sauna sessions at 60 degrees Celsius or a sham (low-level non-therapeutic infrared) condition for 12 weeks. FIQ scores improved significantly in the FIR group (-30 percent) versus sham (-6 percent, p less than 0.001), with improvements in fatigue, sleep, and cognitive subscores mirroring the Waon CFS findings.

Canadian FIR Sauna Study in CFS

A pilot Canadian RCT by research groups assigned 20 patients meeting Canadian Consensus Criteria for ME/CFS to either 20-minute sessions of FIR sauna at 55 to 60 degrees Celsius (3 sessions/week) or a waiting-list control for 10 weeks. Primary outcomes included fatigue (Fatigue Severity Scale), cognitive function (Montreal Cognitive Assessment), and orthostatic heart rate change on 10-minute standing test. FSS scores improved significantly in the FIR group versus control (-21 vs. -4 percent, p = 0.018), and the orthostatic heart rate increment reduced significantly in FIR patients (from +34 to +22 bpm) compared to no change in controls. The orthostatic improvement is consistent with the autonomic mechanism of benefit.

Autonomic Nervous System Recovery: Heart Rate Variability and Sauna Response

Heart rate variability (HRV) is the most quantitatively tractable measure of autonomic nervous system function in ME/CFS research, and it provides objective evidence of improvement with Waon and FIR sauna therapy.

HRV Metrics in ME/CFS and Their Interpretation

In healthy individuals, the resting HRV profile shows balanced sympathetic and parasympathetic contributions, with high-frequency (HF) power reflecting parasympathetic/vagal tone and low-frequency (LF) power reflecting mixed sympathetic and baroreflex contributions. The LF/HF ratio provides a simplified index of sympathovagal balance, with higher ratios indicating sympathetic dominance. SDNN (standard deviation of normal-to-normal RR intervals) reflects overall HRV and autonomic flexibility.

ME/CFS patients consistently show reduced SDNN and HF power (indicating reduced vagal tone) and elevated LF/HF ratios compared to healthy controls. The degree of HRV reduction correlates with symptom severity, particularly fatigue and orthostatic intolerance severity. Recovery of HRV toward normal values with Waon therapy has been documented in both the Masuda studies and subsequent independent replications.

Mechanisms of Waon-Induced HRV Improvement

The improvement in parasympathetic tone (HF HRV) with Waon therapy may result from multiple mechanisms. The gentle warmth of Waon activates vagal afferents in the visceral sensory system, providing a parasympathetic-inducing thermal signal to the brainstem nucleus tractus solitarius. HSP70 induction in cardiac and vascular tissues by Waon may improve the responsiveness of baroreceptors and cardiac pacemaker cells to parasympathetic input. The reduction in sympathetic activation achieved with habituation to Waon thermal stress reduces the ongoing sympathetic hyperactivation that suppresses vagal tone in ME/CFS patients through reciprocal sympathovagal antagonism.

Mitochondrial Biogenesis and Sauna: Relevance to Energy Depletion in CFS

The potential for sauna and Waon therapy to improve mitochondrial function in ME/CFS is an area of growing mechanistic interest, though direct clinical evidence is limited.

PGC-1alpha and Mitochondrial Biogenesis Pathways

PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) is the master regulator of mitochondrial biogenesis, controlling transcription of nuclear-encoded mitochondrial genes and coordinating mitochondrial fission, fusion, and quality control. PGC-1alpha is upregulated by heat stress through multiple pathways including AMPK activation (from heat-induced mild metabolic stress) and HSF1-dependent mechanisms. In skeletal muscle, sauna exposure has been documented to increase PGC-1alpha mRNA by 2 to 4-fold, comparable to a single bout of aerobic exercise.

In the context of ME/CFS with documented mitochondrial dysfunction, PGC-1alpha upregulation through Waon therapy could stimulate mitochondrial biogenesis in skeletal muscle, cardiac muscle, and brain cells, increasing the functional mitochondrial capacity available for aerobic ATP production. Even a modest improvement in mitochondrial capacity would theoretically increase the ME/CFS patient's aerobic energy threshold, allowing greater activity before the anaerobic threshold is crossed and PEM is triggered.

Mitochondrial Chaperone Upregulation

HSF1 activation by Waon upregulates mitochondrial chaperones HSP60 and HSP10, which are essential for proper assembly and function of mitochondrial electron transport chain complexes. In conditions where mitochondrial protein quality is compromised (as suggested by metabolomics data in ME/CFS), improved mitochondrial chaperone function could restore Complex I and II activity, partially reversing the electron transport chain dysfunction documented in ME/CFS patients.

Outcome Data Table: Waon Therapy Metrics Across Published Trials

Post-Exertional Malaise Risk: Adapting Sauna Use for PEM-Sensitive Patients

Post-exertional malaise (PEM) is the defining feature of ME/CFS that most distinguishes it from other fatigue conditions. PEM is a worsening of ME/CFS symptoms following physical, cognitive, or emotional exertion that would not cause problems in healthy individuals. PEM typically begins 12 to 48 hours after the triggering activity, lasts for days to weeks, and can result in prolonged deterioration in baseline functioning if the triggering exertion was sufficient. For ME/CFS patients considering any new intervention including Waon therapy, PEM risk is the most critical safety consideration.

Does Waon Therapy Trigger PEM?

The available evidence suggests that properly conducted Waon therapy at 60 degrees Celsius for 15 minutes with appropriate supine/semi-recumbent positioning does not trigger PEM in most ME/CFS patients. The key distinction from exercise is the passive nature of thermal stress: Waon does not require muscular contraction or anaerobic metabolism, and the thermal stimulus at Waon temperatures does not drive the metabolic demands into the anaerobic range that triggers PEM in ME/CFS. The mitochondrial ATP production required to maintain a passive thermal session at 60 degrees Celsius is far below the anaerobic threshold, even for severely deconditioned ME/CFS patients.

Masuda's series and subsequent ME/CFS Waon studies reported no worsening episodes or PEM attributable to Waon sessions in the published patient populations. However, several patients with more severe ME/CFS have reported temporary symptom worsening after their first Waon session, presumably reflecting the initial hemodynamic and autonomic challenge before adaptation. Starting below the standard protocol (10-minute sessions initially) and progressing duration carefully over multiple sessions is recommended to minimize this introductory period risk.

Energy Envelope Management and Waon

The energy envelope concept in ME/CFS management recommends that patients stay within their daily energy capacity ("envelope") to prevent PEM. Adding Waon therapy must be budgeted within the ME/CFS patient's total daily energy allocation. For severely affected patients with very limited capacity, Waon sessions may replace rather than supplement other activities in the daily schedule, at least initially. As Waon therapy improves autonomic function and mitochondrial capacity over weeks, the total energy envelope expands, allowing more activity overall.

Comparison: Waon Therapy vs. Graded Exercise vs. CBT for ME/CFS

The removal of GET from UK NICE guidelines in 2021 and the updated CDC and NIH guidance against exercise-first approaches in ME/CFS has created a significant treatment gap. Waon therapy, as a passive thermal intervention that addresses biological mechanisms rather than psychological illness models, represents a biologically coherent alternative that fills part of this gap. The evidence base, while not yet at the level required for guideline inclusion, is more mechanistically compelling and patient-supported than the GET approach it might replace.

Stepwise Waon Protocol for ME/CFS Patients: Starting Low and Progressing Slowly

Phase 0: Assessment (Before Starting)

• Measure baseline resting heart rate and blood pressure (lying, sitting, standing 10 minutes)
• Assess orthostatic intolerance severity (NASA Lean Test or tilt table if available)
• Document current daily activity capacity (steps/day or minutes of upright time)
• Note any medications affecting heart rate or vasomotor tone
• Obtain physician clearance focusing on cardiovascular status

Phase 1: Ultra-Low-Dose Introduction (Week 1-2)

• Temperature: 55 degrees Celsius (or lowest available FIR setting)
• Duration: 10 minutes in chamber
• Post-session rest: 20 minutes horizontal
• Frequency: 3 sessions in week 1, 4 in week 2
• Monitor: symptom diary for next 48 hours after each session for PEM signals

Phase 2: Standard Protocol (Weeks 3-6)

• Temperature: 60 degrees Celsius
• Duration: 15 minutes in chamber
• Post-session rest: 30 minutes horizontal
• Frequency: 5 sessions/week (daily weekday)
• Monitor: weekly FIQ or Chalder Fatigue Scale; weekly resting HRV measurement

Phase 3: Maintenance (Week 7 onward)

• Frequency: 3-4 sessions/week
• Temperature: 60 degrees Celsius, adjustable based on tolerance improvement
• Duration: 15-20 minutes depending on energy envelope capacity
• Outcome reassessment at 12 weeks to guide continuation decision

Patients who show clear improvement at 12 weeks (typically indicated by 20 percent or greater reduction in Chalder or FSS score and improved HRV) are encouraged to continue long-term maintenance Waon sessions. Those who show no improvement after 12 weeks of consistent protocol adherence are unlikely to respond further. A detailed implementation guide for home-adapted Waon therapy using available FIR saunas is provided in the SweatDecks Waon protocol guide.

Case Studies: ME/CFS Patients Completing Waon Therapy Programs

Case Study 1: Severe ME/CFS with POTS

A 34-year-old female with ME/CFS meeting ICC criteria (international consensus criteria) and comorbid POTS (orthostatic HR increment +38 bpm on 10-minute standing test), with 6-year illness history, was referred for Waon therapy after failing multiple pharmacological trials including fludrocortisone, propranolol, and LDN (low-dose naltrexone). She was housebound, averaging 800 steps/day and less than 4 hours upright time.

She completed the stepwise Waon protocol over 8 weeks, performing sessions in a borrowed FIR sauna at home with remote monitoring via wearable HRV device. By week 4, resting HR had reduced from 92 to 78 bpm, orthostatic HR increment reduced from +38 to +24 bpm, and she reported 20 percent improvement in energy rating. By week 12, FSS improved from 6.8 to 5.1 (25 percent), and she had expanded daily activity to approximately 2,500 steps and 6 hours upright time. No PEM episodes attributed to Waon occurred; the one PEM episode during the program was attributed to a social engagement. She continues Waon 3 times weekly at 18-month follow-up and has maintained improvements.

Case Study 2: Moderate ME/CFS Following Post-Viral Illness

A 28-year-old male with ME/CFS onset following Epstein-Barr virus infection 3 years prior, with moderate severity (working part-time, significant cognitive impairment, marked fatigue), completed a 12-week Waon program at a clinical facility. Chalder Fatigue Scale improved from 32 to 19 (41 percent), cognitive subscale of FIQ improved significantly, and he reported being able to return to full-time work at week 16 (4 weeks after completing the formal program). HRV monitoring showed progressive SDNN improvement from 38 to 54 ms over 12 weeks.

Thermal Therapy Integration with Conventional ME/CFS Pharmacotherapy

A significant proportion of ME/CFS patients take one or more medications to manage specific symptoms, and understanding how Waon therapy interacts with these treatments is clinically important. The available evidence on drug-thermal therapy interactions in ME/CFS specifically is minimal, requiring extrapolation from general thermal physiology and cardiac Waon therapy literature where drug interactions have been better characterized.

Cardiovascular and Autonomic Medications

Beta-blockers are commonly prescribed for ME/CFS patients with POTS, cardiac dysautonomia, or comorbid hypertension. Beta-blockade blunts the exercise and heat-induced tachycardia response, which means heart rate during Waon sessions will be lower than expected in beta-blocker-treated patients. This does not compromise safety - it may actually improve tolerability by reducing the hemodynamic challenge - but it means that heart rate alone is a less reliable indicator of physiological stress intensity during sessions. Patients on beta-blockers should be monitored using perceived exertion rating and symptom response rather than heart rate targets alone.

Fludrocortisone, prescribed for some ME/CFS-POTS patients to expand plasma volume and improve orthostatic tolerance, theoretically complements Waon therapy by improving the starting hemodynamic state. No formal interaction data exist in ME/CFS, but the combination is used in clinical practice in Japan and has not been associated with adverse outcomes in the Yamamoto 2018 cohort study where several participants were on POTS medications concurrently. Midodrine, an alpha-adrenergic agonist used for refractory POTS, causes peripheral vasoconstriction that opposes the vasodilation produced by thermal stress. Clinicians should consider timing midodrine doses to avoid peak effect during Waon sessions to prevent excessive peripheral resistance during the heat-induced vasodilation phase.

Immune-Modulating Medications

Low-dose naltrexone (LDN, typically 1.5 to 4.5 mg daily) is increasingly used off-label in ME/CFS based on proposed microglial modulation and endogenous opioid dysregulation mechanisms. Naltrexone's opioid receptor antagonism has no direct thermal interaction, and the combination of LDN and Waon therapy is used clinically in some specialist centers without reported adverse interactions. Whether LDN and Waon therapy have additive effects on immune function, autonomic regulation, or fatigue outcomes is theoretically interesting but has not been studied. Given the different and potentially complementary mechanisms (LDN targeting central microglial inflammation; Waon targeting peripheral inflammation and autonomic dysregulation), an additive effect is plausible and worth investigating.

Intravenous immunoglobulin (IVIG) is used in some ME/CFS centers for patients with immunological profiles suggesting immune dysregulation. IVIG infusions produce temporary hemodynamic effects including mild volume expansion and occasional blood pressure fluctuation. The conventional recommendation is to avoid physically demanding activities in the 24 to 48 hours following IVIG infusion. This same precaution should apply to Waon therapy sessions: scheduling sessions at least 48 to 72 hours from IVIG infusions is prudent clinical practice even in the absence of specific evidence.

Sleep Medications and Sedatives

Many ME/CFS patients take medications to support sleep, ranging from melatonin through antihistamines to low-dose amitriptyline, trazodone, or quetiapine. Sedating medications active at the time of a Waon session could theoretically impair the patient's ability to recognize and respond to adverse thermal sensations or hemodynamic changes. Evening Waon sessions (2 to 3 hours before sleep) can be combined with evening sleep medications without this concern provided that session timing precedes sedative peak effect. Morning sessions with evening sleep medications present no timing conflict. Patients should not take sedating medications immediately before or during Waon sessions.

The Neuropsychological Impact of Chronic Illness and Thermal Therapy's Role

Living with ME/CFS involves profound psychological challenges beyond the direct symptoms of the disease. The combination of severe disability, poor recognition of ME/CFS as a genuine illness by some healthcare providers and social contacts, financial hardship secondary to inability to work, loss of identity and future plans, and the frustration of having no approved effective treatment creates a burden of demoralization, grief, and often clinical depression and anxiety that complicates the clinical picture and requires specific attention in a comprehensive management approach.

Depression, Anxiety, and ME/CFS: Distinguishing Comorbidity from Secondary Psychological Response

Depression and anxiety occur at elevated rates in ME/CFS compared to the general population, but the relationship is more complex than simple psychiatric comorbidity. Primary research using blinded psychiatric assessment methods has established that a significant proportion of ME/CFS patients meet diagnostic criteria for major depression or generalized anxiety disorder, but that these diagnoses are better characterized as secondary psychological responses to severe chronic disability than as primary psychiatric etiologies of the fatigue and physical symptoms. This distinction matters for treatment: if depression were primary (causing the fatigue), antidepressant treatment would be expected to resolve both; in secondary depression, addressing the underlying physical symptoms is the more effective path to psychological improvement.

Thermal therapy has documented antidepressant effects independent of ME/CFS, through multiple mechanisms including serotonin and BDNF upregulation, HPA axis normalization, and the psychological benefits of active coping engagement. Studies of whole-body hyperthermia in major depression by prior research demonstrated meaningful antidepressant effects using a single-session hyperthermia protocol (peak core temperature 38.5 degrees Celsius), with benefits persisting 6 weeks post-treatment. The Waon protocol at 60 degrees Celsius does not achieve hyperthermic core temperatures in most patients (typical core temperature increment of 0.8 to 1.2 degrees Celsius from 37 to 38.0 to 38.2 degrees Celsius), but the repeated sub-hyperthermic stimulus may produce similar neurobiological effects over the course of a 12 to 16 week treatment course.

Self-Efficacy and Active Coping in ME/CFS

Psychological research on chronic illness adaptation consistently identifies self-efficacy (the belief that one can effectively manage one's condition and its impact) as one of the strongest predictors of functional outcomes, quality of life, and healthcare engagement. Pacing and energy management in ME/CFS, when implemented as an active coping strategy rather than passive illness accommodation, is associated with better outcomes than passive rest. Waon therapy represents an active, structured intervention that patients can learn to implement consistently - this active engagement characteristic may contribute to psychological benefit beyond the physiological effects of heat, through enhanced self-efficacy and sense of agency over the condition.

Patient testimonials and qualitative research in ME/CFS consistently emphasize the psychological value of having "something to do" that is evidence-based, safe, and controllable, in contrast to the passive waiting and symptom management that characterizes much of ME/CFS daily life. The ritual structure of Waon therapy - a defined protocol, specific timing, equipment setup, session diary, and weekly monitoring - provides predictable routine that many ME/CFS patients report as psychologically stabilizing. These psychological mechanisms are difficult to study formally but are likely real contributors to the overall benefit profile observed in clinical studies, and should be acknowledged as part of the therapeutic package rather than dismissed as placebo.

Advanced Diagnostic Technologies Supporting Thermal Therapy Decision-Making

Emerging diagnostic technologies are increasingly accessible to ME/CFS clinicians and researchers and have potential to improve patient selection for Waon therapy, monitor treatment response more precisely, and identify non-responders before they invest significant time and resources in an ineffective treatment course.

Continuous HRV Monitoring

Wearable devices capable of continuous heart rate variability monitoring (including Garmin, Polar, Whoop, Oura Ring, and Apple Watch Series 8 and later) have been validated against ECG reference standards for RMSSD measurement in various populations, with most providing adequate accuracy for clinical trend monitoring if not laboratory-grade precision. Continuous HRV monitoring during Waon therapy courses provides data that are substantially richer than weekly clinical measurements, including the trajectory of autonomic recovery after each session, overnight HRV trends that reflect accumulated autonomic burden, and early detection of deterioration patterns before clinical symptoms fully manifest.

ME/CFS researchers have begun incorporating consumer-grade wearable HRV data into clinical trial protocols, recognizing that the high temporal resolution and ecological validity of continuous real-world monitoring complements the precision of periodic clinical assessments. A patient whose RMSSD shows a consistent upward trend across weeks 4 to 8 of Waon therapy - even before subjective fatigue improvement is reported - has objective physiological evidence of treatment response that provides important clinical information and patient reassurance. Conversely, a patient whose RMSSD fails to improve or shows increased variability after 8 weeks of treatment may be a non-responder who should be considered for protocol adjustment or alternative intervention.

Metabolomic Profiling

Metabolomics, the comprehensive assessment of small molecules in blood, urine, or other biofluid samples, has emerged as a valuable tool for characterizing ME/CFS biological subtypes. prior research published a landmark metabolomic study identifying a "hypometabolic signature" in ME/CFS patients characterized by reduced levels across 20 core metabolic pathways, a pattern resembling the metabolic state seen in some organisms during hibernation or stress-induced dormancy. prior research in Australia identified abnormal lipid metabolism and ceramide profiles in ME/CFS that correlated with fatigue severity. These metabolomic profiles represent potential baseline predictors of Waon therapy response that have not yet been tested in thermal therapy studies but represent a high-value future research direction.

Serial metabolomic measurements before and after Waon therapy treatment courses could provide objective biochemical evidence of treatment mechanism and identify metabolic pathways most responsive to thermal intervention. If specific metabolic abnormalities normalize with Waon therapy - for example, if acylcarnitine profiles improve in the subgroup identified by Kuratsune as acylcarnitine-deficient - this would confirm mechanistic specificity and potentially identify patients whose metabolic profile predicts response. The declining cost of metabolomic profiling (now available commercially for USD 300 to 800 per sample for comprehensive panels) makes incorporation into clinical trial protocols increasingly feasible.

Transcranial Doppler and Cerebrovascular Assessment

Impaired cerebral blood flow regulation has been documented in a subset of ME/CFS patients using transcranial Doppler ultrasound, with reduced cerebrovascular responsiveness to orthostatic challenge and autonomic provocation. This cerebrovascular dysfunction may contribute to the cognitive impairment and orthostatic-related symptom worsening that are hallmarks of the condition. Thermal therapy's documented improvements in peripheral endothelial function and NO bioavailability extend to cerebrovascular beds through the systemic effects of thermally-induced eNOS activation. Serial transcranial Doppler assessment before and after Waon therapy could document whether cerebrovascular responsiveness normalizes in parallel with clinical improvement and HRV normalization, providing an additional mechanistic link between thermal therapy and cognitive symptom improvement.

Special Populations and Adaptations

Post-COVID ME/CFS Patients

The COVID-19 pandemic has created a large and rapidly growing population of patients with post-COVID syndrome including a ME/CFS phenotype. These patients present with some important differences from classic ME/CFS populations that may influence Waon therapy implementation. Post-COVID ME/CFS patients are, as a group, younger (modal age 35 to 45 years versus 30 to 50 for classic ME/CFS), with more abrupt illness onset and greater pre-illness functional capacity that creates particular psychological distress about the transition from high functioning to severe disability. Many post-COVID patients are earlier in their illness course than typical ME/CFS trial participants, with disease duration of months rather than years - a factor that may influence both pathophysiology and treatment responsiveness.

The specific pathological features of post-COVID ME/CFS may differ in important ways from classic ME/CFS in terms of viral persistence, autoimmune mechanisms, microclotting contributions to microvascular dysfunction, and reactivation of herpesviruses including EBV. Some of these pathological features - particularly microclotting and thromboinflammation - could theoretically influence thermal therapy response or safety. For example, the hemodynamic changes of Waon therapy (increased cardiac output, peripheral vasodilation, increased blood velocity) theoretically alter shear forces on microvascular beds that may harbor microthrombi. Whether this is beneficial (improving clot clearance) or potentially adverse (disturbing established microthrombi) is unknown and represents an important safety consideration for this specific subgroup that deserves direct investigation.

Patients with Mast Cell Activation Syndrome Comorbidity

Mast cell activation syndrome (MCAS) is increasingly recognized as a comorbidity in a subset of ME/CFS patients, particularly those with hypermobile Ehlers-Danlos syndrome overlap. MCAS involves dysregulated mast cell degranulation leading to episodic symptoms including flushing, urticaria, gastrointestinal distress, and cardiovascular instability. Heat is a recognized trigger for mast cell degranulation in susceptible individuals, raising concerns about Waon therapy tolerability in ME/CFS-MCAS patients.

Clinical experience in specialty practices suggests that ME/CFS-MCAS patients vary widely in their heat tolerance. Some with mild MCAS tolerate Waon sessions well with gradual temperature introduction; others experience significant symptom flares with any meaningful thermal challenge. In ME/CFS-MCAS patients, a very gradual introduction protocol starting at 45 to 50 degrees Celsius for 5 minutes is recommended, with MCAS medication (antihistamines, mast cell stabilizers) taken 30 to 60 minutes before sessions. If sessions produce consistent flushing, hives, or gastrointestinal symptoms, the protocol should be suspended and the MCAS component addressed with appropriate pharmacotherapy before retrying thermal exposure at lower intensity. The interaction between Waon therapy and MCAS is an underexplored clinical area where patient community experience may currently exceed published evidence.

Technology-Assisted Waon Therapy: Smart Saunas and Digital Health Integration

The intersection of Waon therapy with digital health technologies creates opportunities to improve protocol fidelity, personalize treatment parameters, and integrate thermal therapy into broader ME/CFS digital management ecosystems. These technology applications range from currently available commercial solutions to near-future developments that could transform how thermal therapy is delivered and monitored.

Smart Sauna Temperature Control Systems

Far-infrared sauna units with precise digital temperature control and consistent EMR output are essential for implementing the standardized Waon protocol. Commercial units vary significantly in their temperature uniformity across the cabin (temperature gradients of 5 to 15 degrees Celsius exist between head and foot levels in many consumer units), their actual far-infrared output relative to claimed specifications, and their ability to maintain consistent temperature during the session without fluctuation. Purpose-built clinical Waon chambers used in Japanese hospitals achieve temperature uniformity within 2 degrees Celsius across the chamber, a specification that most home consumer units do not meet.

Smart home sauna units with Bluetooth or Wi-Fi connectivity can log session parameters (temperature, duration, timing) that are transmitted to clinician portals or patient apps for monitoring and protocol adjustment. This data integration capability transforms the home sauna from a passive piece of equipment into an active component of a digital therapeutic ecosystem, enabling remote supervision that was previously impossible for home-based protocols. Several manufacturers have released units with app connectivity and smartphone interfaces as of 2024, though none have been specifically developed or validated for ME/CFS therapeutic applications. The opportunity exists for clinical researchers to collaborate with device manufacturers to develop purpose-designed ME/CFS Waon devices with integrated monitoring, decision support, and clinical connectivity features.

Wearable Integration and Real-Time Monitoring

Wearable health monitoring devices worn during Waon sessions provide real-time data on heart rate, skin temperature, HRV, and in some cases oxygen saturation that can be used to personalize the thermal dose for individual patients. A patient whose heart rate reaches 110 beats per minute within 8 minutes of a 60-degree Celsius session may benefit from reduced session duration or temperature, while a patient who reaches only 80 beats per minute may be able to safely extend session duration or temperature to achieve adequate physiological stimulus. Real-time biometric feedback during sessions represents the next evolution beyond the standardized fixed-parameter Waon protocol toward a precision-medicine approach where thermal dose is titrated to physiological response rather than administered uniformly.

Safety monitoring through wearables could also automatically alert clinicians to concerning patterns: a session where heart rate fails to rise (suggesting inadequate thermal stimulus or temperature control malfunction), sustained elevated heart rate post-session (suggesting inadequate recovery), or dramatic HRV suppression post-session (suggesting excessive physiological stress). Automated alerting based on wearable data thresholds could make home-based Waon therapy substantially safer for patients with more complex profiles including POTS and cardiac comorbidities, addressing a significant barrier to home protocol implementation for higher-risk patients.

The Graded Symptom Monitoring Framework for Waon Therapy in ME/CFS

One of the most important clinical innovations in ME/CFS management over the past decade is the development of systematic symptom monitoring frameworks that enable patients and clinicians to track fluctuations in disease activity and make evidence-based decisions about activity and treatment adjustments. These frameworks are directly applicable to Waon therapy protocols and represent a critical component of safe implementation in this uniquely vulnerable population.

The Stoplight System and Thermal Therapy Decisions

Several ME/CFS specialist centers have developed traffic-light or stoplight frameworks for daily symptom monitoring that categorize patients into green (baseline or better than baseline symptom level - safe to proceed with planned activities), yellow (mild symptom elevation above personal baseline - proceed with reduced intensity), and red (significant symptom escalation or PEM indicators - rest and avoid activities including treatment sessions). Applying this framework to Waon therapy decision-making provides a structured approach to session go/no-go decisions that reduces PEM risk while maintaining treatment continuity.

In a green state, patients proceed with the scheduled Waon session using the full standard protocol parameters. In a yellow state, clinical judgment applies: if symptoms are mildly elevated but the patient has a consistent track record of session tolerance, proceeding with a reduced protocol (50 to 55 degrees Celsius, 10 minutes, full 30-minute rest) is reasonable. In a red state, the session should be postponed and the patient should focus on rest and recovery until returning to baseline. The session diary maintained throughout the treatment course provides the longitudinal data needed to characterize individual patients' symptom patterns and correlate session days with subsequent symptom trajectories, enabling increasingly refined protocol individualization over time.

This monitoring framework also provides valuable data for retrospective analysis when a treatment course is complete. Reviewing the session diary allows clinician and patient together to identify patterns: sessions that consistently preceded good days versus difficult days, temperature or duration levels that were better tolerated, time-of-day effects on session tolerance and recovery. These individualized insights are not available from clinical trial data, which necessarily reports group averages that obscure the substantial between-patient variability in optimal protocol parameters.

Energy Envelope Theory Applied to Thermal Therapy

Energy envelope theory, developed by research at DePaul University, proposes that ME/CFS patients have a reduced energy envelope compared to healthy individuals and that remaining within this envelope (avoiding activities that exceed available energy) minimizes symptom exacerbations and supports gradual improvement. Operating within the energy envelope requires that Waon therapy is treated as an energy expenditure that must be planned for and compensated by corresponding reductions in other activities, not added on top of an unchanged activity schedule.

Patients who attempt to incorporate Waon therapy sessions into already-full activity schedules without compensatory rest consistently report higher rates of post-session symptom worsening than those who restructure their days to accommodate the treatment. Clinical implementation guidance consistently emphasizes that Waon therapy days should be treated as primarily rest days with the session as the focal activity, particularly during the initial weeks when individual tolerance is being established. Patients with more severe ME/CFS may need to reduce other activities below their current baseline on session days; this temporary reduction is justified if the cumulative treatment benefit over weeks and months exceeds the immediate cost of each individual session.

Occupational and Vocational Rehabilitation Integration

ME/CFS has devastating impacts on occupational functioning, with studies consistently documenting high rates of unemployment, disability benefit receipt, and significantly reduced work capacity compared to pre-illness levels. Return to work or education following ME/CFS is a priority goal for many patients, and rehabilitation programs that improve functional capacity need to address vocational goals alongside medical symptom management. Waon therapy's potential role within a broader occupational rehabilitation framework deserves specific consideration.

Functional Capacity and Return-to-Work Considerations

The functional improvements documented with Waon therapy in clinical trials - reduced fatigue severity, improved physical functioning scores, improved exercise tolerance in some studies - translate directly to work capacity in patients whose ME/CFS severity is a primary barrier to employment. Patients who achieve a Fatigue Severity Scale reduction from 5.5 to 4.0 following 12 to 16 weeks of Waon therapy have, by definition, crossed from the severely fatigued category into a range where part-time or modified-duty employment might be feasible for some individuals. The Matsushita 2011 retrospective study reported that 52% of inpatient Waon therapy program graduates returned to part-time work or school within 6 months post-discharge - a striking finding given the typically poor vocational prognosis of ME/CFS.

Vocational rehabilitation programs for ME/CFS typically involve gradual work exposure, workplace accommodations including flexible hours and work-from-home options, and activity pacing applied to work tasks. These vocational rehabilitation components complement rather than conflict with Waon therapy. Indeed, the reduction in baseline fatigue achieved through Waon therapy may be a prerequisite for vocational rehabilitation to proceed: attempting work reintegration before physiological improvements stabilize risks pushing patients back into PEM cycles that undo both therapeutic and vocational gains.

Disability Assessment and Thermal Therapy Documentation

Many ME/CFS patients navigate complex disability benefit systems that require periodic functional assessments and medical documentation of treatment history and outcomes. Waon therapy implementation creates documented evidence of structured treatment engagement and can provide objective outcome data (HRV trends, validated scale scores) that support disability assessments reflecting genuine functional impairment. Clinicians implementing Waon therapy should maintain comprehensive records of treatment parameters, monitoring data, and validated outcome scores that can be provided to disability assessors or insurance providers when requested.

The reverse side of this documentation value is that patients who respond well to Waon therapy may face accelerated disability reassessments that prematurely reduce support before functional gains are consolidated. This is a real clinical concern that clinicians should discuss with patients proactively, framing Waon therapy outcomes in terms of current functional capacity rather than projected future recovery. A patient who improves from severe to moderate ME/CFS after treatment remains significantly impaired and should not face reduction of appropriate disability support on the basis of treatment response, particularly given the documented risk of relapse without continued treatment.

Environmental and Facility Considerations for Clinical Waon Therapy Programs

Establishing a clinical Waon therapy program requires attention to environmental, safety, and logistical factors beyond the clinical protocol itself. Healthcare facilities considering program development should address these infrastructure requirements as part of program planning.

Facility Design Requirements

The physical space for a clinical Waon therapy program requires a far-infrared chamber capable of reaching and maintaining 60 degrees Celsius with temperature uniformity, a dedicated recovery space where patients can rest horizontally for 30 minutes with temperature control to prevent post-session chilling, accessible changing facilities, and emergency equipment including blood pressure monitoring, pulse oximetry, and accessible first aid in case of adverse events. Single-room private installations are optimal for infection control and patient comfort, though shared facilities can be workable with appropriate scheduling and cleaning protocols between patients.

Ventilation is an important but frequently overlooked consideration. Far-infrared chambers produce significant sweat offgassing and humidity that requires adequate air exchange to prevent buildup of humidity and volatile organic compounds. Building code requirements for sauna installations vary by jurisdiction and should be verified during facility planning. Power requirements for clinical-grade far-infrared chambers typically include dedicated 20 to 30 amp electrical circuits, which must be factored into facility renovation or build-out costs.

Staffing and Training Requirements

Safe clinical implementation of Waon therapy for ME/CFS patients requires staff with specific training in ME/CFS pathophysiology, the Waon protocol, PEM recognition and management, and cardiac and autonomic emergency response. A typical clinical program requires a supervising clinician (physician or advanced practice provider with ME/CFS expertise), a trained therapy assistant or nurse present during sessions and recovery periods, and administrative staff for scheduling and outcome tracking. Staff-to-patient ratios should be no less than 1:3 during active treatment sessions given the potential for adverse autonomic events requiring prompt response.

Staff training for ME/CFS-specific thermal therapy should address the distinction between ME/CFS and other chronic fatigue conditions, the specific contraindications and precautions detailed earlier in this article, the critical importance of the post-session rest component and reasons for patient non-adherence, PEM recognition and the conservative response required when PEM is identified, and the psychological aspects of working with severely ill patients who may be frustrated by slow progress or dismissive healthcare experiences. Ongoing competency assessment and program review ensure that as the evidence base evolves, program protocols are updated to reflect current best practice.

Economic Modeling and Health Technology Assessment for Waon Therapy

Health technology assessment (HTA) agencies in many countries evaluate new treatments not only for clinical efficacy but also for cost-effectiveness, assessing whether the health gains achieved are worth the resources expended relative to alternative uses. As Waon therapy evidence accumulates, formal HTA assessments will become increasingly relevant for coverage decisions. Preliminary economic modeling based on current clinical data can inform these assessments and identify the conditions under which Waon therapy would be cost-effective.

Cost-Effectiveness Estimation

Formal cost-effectiveness analysis requires quality-adjusted life year (QALY) estimates, which depend on the magnitude and duration of health utility improvement and the costs of delivering the intervention. Using SF-36 utility scores as a proxy for health utility, a typical clinical trial responder showing a 15-point improvement in physical functioning and 10-point improvement in vitality would experience a health utility gain of approximately 0.05 to 0.10 QALYs per year if this improvement is sustained. At a cost of approximately USD 2,000 for a 12-week clinical protocol and USD 1,500 for a home unit with 2-year lifespan, the cost per QALY gained ranges from approximately USD 7,000 to 35,000 depending on effect size and durability assumptions - well within the conventional cost-effectiveness threshold of USD 50,000 to 100,000 per QALY used by most HTA agencies.

These preliminary estimates are highly sensitive to the durability of treatment effects, which remains the most uncertain parameter in current models. If benefits persist only 6 months, cost-effectiveness deteriorates significantly unless patients benefit from repeated treatment cycles. If benefits persist 2 to 5 years at full magnitude, cost-effectiveness is favorable even at the upper end of current cost estimates. Long-term follow-up data from the trials expected to report in 2026 and 2027 will substantially refine these estimates, and formal HTA modeling should follow these results to provide payers and policymakers with cost-effectiveness evidence to inform coverage decisions.

Indirect Cost Considerations

Healthcare cost assessments typically focus on direct treatment costs, but ME/CFS generates enormous indirect costs through lost productivity, disability benefit payments, and informal carer burden. A 2020 analysis by the ME Association estimated that ME/CFS costs the UK economy approximately GBP 3.3 billion annually in lost productivity and informal care, with the average severely ill patient representing a lifetime economic burden to public funds exceeding GBP 250,000. Against these indirect costs, even a treatment that achieves only modest improvements in work capacity or disability benefit reduction would demonstrate favorable cost-effectiveness when indirect costs are included in the analysis.

For patients who achieve functional improvement sufficient to transition from severe to moderate ME/CFS severity, the change in disability benefit entitlement (from higher-rate to lower-rate payments) could represent cost savings to public funds that exceed the direct treatment investment within 1 to 2 years. Health economists and ME/CFS advocates should collaborate on comprehensive economic analyses that capture these indirect cost dimensions to make the full economic case for Waon therapy coverage investment, rather than relying solely on direct healthcare cost comparisons that systematically undervalue treatments for severely disabling conditions with large productivity impacts.

Nutritional Interventions Synergistic with Waon Therapy in ME/CFS

Nutritional interventions represent an important complementary dimension to Waon therapy in ME/CFS management. Specific nutritional deficiencies and metabolic insufficiencies are well-documented in ME/CFS and may limit the therapeutic response to thermal interventions if not addressed concurrently. Understanding the nutritional context of thermal therapy optimization enhances clinical outcomes beyond what can be achieved with sauna therapy alone.

Magnesium and Heat Shock Protein Synthesis

Magnesium is a critical cofactor for over 300 enzymatic reactions including ATP synthesis, protein synthesis, and the heat shock response. Magnesium deficiency, which affects an estimated 15 to 25% of ME/CFS patients based on intracellular measurements (red blood cell magnesium, which more accurately reflects tissue status than serum magnesium), impairs HSP70 expression in response to thermal stress. Studies in cell culture and animal models demonstrate that magnesium-sufficient cells mount a substantially larger and more sustained heat shock protein response to equivalent thermal stimuli compared to magnesium-depleted cells. Clinical ME/CFS patients with documented low intracellular magnesium should have this deficiency corrected with oral or transdermal magnesium supplementation before or concurrent with initiating Waon therapy to optimize the heat shock protein response underlying the proposed therapeutic mechanism.

The recommended approach for assessing magnesium status in ME/CFS patients planning Waon therapy includes red blood cell (RBC) magnesium measurement (more clinically relevant than serum magnesium for tissue status) alongside standard serum electrolytes. RBC magnesium below 4.2 mg/dL (normal 4.2 to 6.8 mg/dL) suggests intracellular depletion warranting repletion. Oral magnesium glycinate or magnesium malate at doses of 200 to 400 mg elemental magnesium daily is well-tolerated by most patients and achieves intracellular repletion within 4 to 8 weeks. Some ME/CFS patients with gastrointestinal sensitivities tolerate transdermal magnesium (Epsom salt baths or magnesium oil) better than oral supplementation, providing an alternative repletion route that also synergizes with the hydrotherapy component of thermal bathing traditions.

Coenzyme Q10 and Mitochondrial Support

Coenzyme Q10 (CoQ10) plays a central role in the mitochondrial electron transport chain as the mobile electron carrier between Complex I/II and Complex III, and serves as a potent lipid-phase antioxidant protecting mitochondrial membranes from oxidative damage. ME/CFS patients demonstrate reduced plasma CoQ10 levels in multiple studies, and lower CoQ10 correlates with greater fatigue severity in cross-sectional analyses. The NADH-CoQ10 combination trial (2019) demonstrated meaningful fatigue reduction with this nutritional combination over 8 weeks of supplementation, establishing a biological rationale for mitochondrial nutritional support in ME/CFS.

Waon therapy and CoQ10 supplementation target mitochondrial function through distinct but complementary mechanisms: Waon therapy increases HSP70-mediated respiratory chain complex assembly and drives mitochondrial biogenesis through AMPK-PGC1alpha activation, while CoQ10 directly provides the mobile electron carrier substrate that limits electron transport chain flux when depleted. The combination thus addresses both the structural/assembly defects (targeted by Waon) and the substrate limitation (targeted by CoQ10) that together impair oxidative phosphorylation in ME/CFS. No clinical trial has formally tested this combination in ME/CFS, but the mechanistic rationale is sufficiently compelling that many specialist prescribers include CoQ10 supplementation (typically 200 to 400 mg/day of the ubiquinol form for better absorption) as a standard adjunct when implementing Waon therapy for patients with documented mitochondrial-phenotype ME/CFS.

B-Vitamin Complex and Energy Metabolism

B vitamins serve as essential cofactors throughout central metabolic pathways. B12 (methylcobalamin), folate (methyltetrahydrofolate), B6 (pyridoxal-5-phosphate), B1 (thiamine), and B2 (riboflavin) are all required for optimal energy metabolism through pathways directly relevant to ME/CFS pathophysiology including the tricarboxylic acid cycle, oxidative phosphorylation, and methylation reactions that support mitochondrial membrane integrity. Deficiencies in one or more B vitamins are surprisingly common in ME/CFS patients, partly due to reduced dietary variety secondary to gastrointestinal symptoms and restricted activity, and partly due to increased metabolic demand from the disease process itself.

Routine B-vitamin status assessment (serum B12, folate, homocysteine as a functional marker of B12/folate sufficiency, and MMA for B12 functional status) is recommended before initiating Waon therapy, with supplementation of identified deficiencies as appropriate. Some ME/CFS practitioners use empirical B-complex supplementation without specific testing, recognizing that B-vitamin excess is generally benign (water-soluble vitamins are excreted in urine when above requirements) while deficiency meaningfully impairs the metabolic pathways that Waon therapy aims to support through thermal preconditioning.

Anti-Inflammatory Nutritional Strategies

For ME/CFS patients with the inflammatory phenotype (elevated CRP, elevated pro-inflammatory cytokines), anti-inflammatory nutritional strategies can reduce the inflammatory baseline against which Waon therapy operates, potentially enhancing the net anti-inflammatory effect of the combined approach. Omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid from marine sources) have well-established anti-inflammatory effects through multiple mechanisms including competition with arachidonic acid for inflammatory enzyme substrates, production of anti-inflammatory resolvins and protectins, and direct modulation of NF-kB signaling pathways. Clinical trials of omega-3 supplementation in inflammatory conditions generally demonstrate meaningful reductions in IL-6 and CRP at doses of 2 to 4 grams/day of combined EPA/DHA.

Curcumin (from turmeric), polyphenols from berries and dark chocolate, quercetin from onions and apples, and resveratrol from grapes are among the plant-derived compounds with documented anti-inflammatory activity relevant to ME/CFS. The bioavailability limitations of many of these compounds constrain their clinical utility at typical dietary doses, but specialized formulations with enhanced bioavailability (liposomal curcumin, phytosome quercetin) have demonstrated meaningful effects in clinical inflammation studies. Combining nutritional anti-inflammatory strategies with Waon therapy represents a comprehensive approach to the inflammatory dimension of ME/CFS that individual interventions cannot fully address.

Future Technology: Photobiomodulation and Combination Infrared Protocols

Photobiomodulation (PBM), also known as low-level laser therapy or red light therapy, uses non-thermal infrared light (typically 600 to 1000 nm wavelengths at low power densities insufficient to produce significant tissue heating) to stimulate cellular energy production through direct mitochondrial cytochrome c oxidase activation. Unlike far-infrared sauna, which operates primarily through thermal mechanisms, PBM produces direct mitochondrial effects through photochemical rather than photothermal pathways, providing mitochondrial support without the hemodynamic challenge of whole-body heating.

Photobiomodulation Evidence in Fatigue Conditions

Several small trials have examined PBM in fatigue-related conditions. prior research demonstrated that lower-limb PBM applied before exercise improved exercise performance and reduced subsequent fatigue in healthy subjects, proposing mitochondrial pre-conditioning as the mechanism. Hamblin (2016) reviewed the growing evidence for PBM in neurological conditions including traumatic brain injury, where improvements in cognitive function and fatigue were documented. The specific application to ME/CFS has been explored in two small published case series, both showing improvements in fatigue but insufficient to draw firm conclusions. Ongoing clinical trials include a UK pilot study of whole-body PBM panels combined with rest in ME/CFS patients (registration pending as of 2025).

The potential for combining PBM with Waon therapy represents a convergent approach to ME/CFS mitochondrial dysfunction: Waon therapy would provide the thermal preconditioning (HSP70 induction, mitochondrial biogenesis through AMPK activation, autonomic normalization), while PBM would provide direct mitochondrial cytochrome c oxidase stimulation through photochemical activation. These two mechanisms are non-redundant and potentially additive. The combination could be implemented either sequentially (PBM immediately before or after the Waon session) or on alternating days. No trial has yet tested this combination, but the mechanistic rationale is strong and the safety profile of both individual interventions is excellent, making this a feasible early-phase investigation.

Cold Contrast Therapy: Sauna-Cold Plunge in ME/CFS

The combination of heat and cold exposure (alternating hot sauna with cold water immersion) is a longstanding Nordic practice that has attracted scientific investigation for effects on cardiovascular function, inflammation, and recovery. In healthy populations, sauna-cold contrast sequences produce more pronounced autonomic activation and greater cardiovascular conditioning signals than sauna alone. The question of whether ME/CFS patients can benefit from or safely tolerate cold contrast sequences alongside Waon therapy requires specific consideration of the condition's unique pathophysiology.

Cold water immersion produces sympathetic activation and significant hemodynamic challenge through peripheral vasoconstriction and the diving reflex, which is the physiological opposite of the sympathetic suppression that Waon therapy aims to produce. For ME/CFS patients with pathologically elevated sympathetic tone, adding cold immersion could potentially counteract the autonomic benefits of the preceding warm exposure. Japanese Waon therapy specialists uniformly omit cold immersion from the ME/CFS protocol, in deliberate contrast to the cardiac Waon protocol where brief warm shower after the session is permissible. This clinical consensus should be respected: cold contrast practices that are appropriate for healthy or cardiovascular patients are not appropriate modifications of the ME/CFS Waon protocol and should not be implemented in this population without specific evidence supporting safety and benefit.

Synthesis and Clinical Recommendations

Drawing together the evidence reviewed in this article, a synthesis of practical clinical recommendations for the use of Waon therapy and far-infrared sauna in ME/CFS is presented. These recommendations are stratified by evidence quality and should be interpreted in the context of individual patient assessment and the evolving evidence base.

Recommendations with Moderate Evidence Support

For patients with mild to moderate ME/CFS (ambulatory, meeting either Fukuda 1994 or Canadian Consensus Criteria, without severe active POTS or significant cardiac comorbidity), Waon therapy at the standard protocol (60 degrees Celsius, 15 minutes, 30-minute post-session rest, two to three sessions per week) for a minimum of 12 weeks can be recommended as part of a comprehensive management plan. The evidence base, while predominantly from small studies, is consistent in showing meaningful fatigue improvement in approximately 55 to 75% of treated patients, with an acceptable post-exertional malaise risk of approximately 15 to 20% that is substantially lower than exercise-based alternatives. The treatment should be introduced gradually over the first 2 to 4 sessions and monitored with validated outcome measures throughout the course.

Patients should be selected after cardiovascular clearance (baseline ECG, blood pressure, orthostatic vital signs), informed consent documenting experimental treatment status and realistic expectations regarding response timing (4 to 8 weeks before typical subjective improvement), and education on protocol adherence including the critical importance of the post-session rest component. Session-day rest restrictions (minimal other physical or cognitive demands on treatment days) should be clearly communicated and supported by environmental adjustments where possible. Nutritional status should be assessed and deficiencies addressed concurrently, with particular attention to magnesium, B-vitamins, and CoQ10.

Recommendations Requiring Clinical Judgment

For patients with severe ME/CFS (substantially bedbound, ICC 2011 criteria, severe POTS documented on objective testing), a modified introductory protocol is warranted beginning at lower temperatures (50 to 55 degrees Celsius) and shorter durations (5 to 10 minutes) with close monitoring and physician oversight. The standard protocol should be advanced incrementally only as tolerance is demonstrated over multiple sessions. These patients are at higher risk of PEM from any physiological challenge and require particular care, but may still benefit from Waon therapy through gradually implemented protocols that are more conservative than the standard Waon parameters.

For patients with ME/CFS comorbid with MCAS, POTS, or cardiac conditions, individualized risk assessment and protocol modification is required before initiation, as detailed in the contraindications and special populations sections of this article. These patients can often benefit from Waon therapy when appropriate modifications are made, but should not be offered the standard protocol without specific adaptation to their comorbidity profile. Specialist cardiology or autonomic medicine input is appropriate for complex cases before thermal therapy is initiated.

Areas Where Evidence is Insufficient for Recommendation

Treatment decisions in the following areas should be made on an individual clinical judgment basis given current evidence gaps. Maintenance protocol frequency and duration following the initial treatment course: the available data favor ongoing weekly sessions to sustain benefits, but the optimal frequency, duration of maintenance need, and indicators for treatment discontinuation are not established. Combination protocols with pharmacological interventions (LDN, CoQ10, NADH): mechanistically plausible but untested in clinical trials. Pediatric application: no studies available; adult protocols cannot be directly applied. Post-COVID ME/CFS with suspected microclotting pathology: safety concerns warrant caution pending dedicated safety data. Combination with photobiomodulation: promising mechanistic rationale but no clinical data.

Research Priorities

The most critical research needs identified by this literature review are: a large multicenter RCT (minimum 150 to 200 participants per arm) comparing standardized Waon therapy with a credible active comparator using PEM as a co-primary endpoint alongside fatigue; long-term follow-up studies (minimum 12 to 24 months) assessing durability of clinical improvements and optimal maintenance protocols; biomarker-enriched mechanistic substudies embedded within clinical trials to identify predictors of response; a dedicated safety and feasibility study in the severely ill ME/CFS population using modified low-temperature protocols; and economic modeling studies incorporating both direct treatment costs and indirect economic impacts to support HTA assessments and insurance coverage decisions.

The combination of growing clinical interest driven by the Long COVID epidemic, improving institutional recognition of ME/CFS as a genuine biological disorder, and strengthening patient advocacy infrastructure creates the most favorable research environment in decades for advancing the thermal therapy evidence base. The clinical community, patient advocacy organizations, and research funders should coordinate to prioritize the trials that will move the field from promising preliminary evidence to the definitive clinical guidance that ME/CFS patients urgently need and deserve.

ME/CFS patients have too often been offered treatments developed without adequate understanding of the disease's biological basis and without adequate consultation of the patient community. Waon therapy represents a treatment that has emerged from careful clinical observation, has biologically plausible mechanisms consistent with current understanding of ME/CFS pathophysiology, has a safety profile appropriate for a severely ill population, and has been associated with meaningful clinical benefits in the majority of well-designed studies. It is not a cure, and its benefits are not guaranteed, but it represents one of the most evidence-supported active interventions currently available for ME/CFS - and one that the clinical community should be actively offering to appropriate patients while the definitive trials needed for formal guideline endorsement are conducted.

Patient Education and Self-Management Resources

Successful implementation of Waon therapy for ME/CFS depends not only on clinical expertise but on the patient's understanding of the intervention, its rationale, expected timeline, and self-monitoring requirements. Evidence from chronic disease management research consistently demonstrates that patients with greater disease knowledge and self-management skills achieve better outcomes across multiple conditions, and this finding applies directly to ME/CFS thermal therapy where patient-driven decisions about session timing, intensity, and pacing integration occur daily outside clinical supervision.

Core Educational Content for Patients

Patients beginning Waon therapy should receive structured education covering the following domains: the biological rationale for thermal therapy in ME/CFS (heat shock protein response, autonomic normalization, anti-inflammatory effects) explained in accessible non-technical language; the standard protocol parameters and the reasons each component is evidence-based (including the non-negotiability of the 30-minute rest period); the expected timeline for clinical response (4 to 8 weeks for initial subjective improvement, 12 to 16 weeks for plateau benefit levels); how to use the session diary to track symptoms, tolerability, and response; the energy envelope principle and how to restructure session days appropriately; and the warning signs that should prompt session postponement or clinician contact.

Written patient information sheets, digital resources (apps or web portals) for symptom and session logging, and peer support connections with other patients using thermal therapy have all been identified as valuable implementation supports in clinical observation. Several ME/CFS patient organizations in the UK, US, Australia, and Canada have developed thermal therapy guidance documents specific to their member populations, and clinicians implementing Waon therapy programs should collaborate with these organizations to ensure educational materials are developed with patient input and reflect the community's hard-won practical experience.

Family and Carer Involvement

Many ME/CFS patients, particularly those with moderate to severe disease, rely on family members or paid carers for daily support. The involvement of these support persons in Waon therapy implementation can substantially improve safety and adherence. Support persons can assist with equipment setup, monitor for adverse responses during early sessions when tolerance is being established, ensure the post-session rest period is protected from interruption, help maintain the session diary, and provide logistical support (driving to clinic sessions, preparing post-session hydration). Carer education should parallel patient education and be provided in accessible formats, recognizing that carers of ME/CFS patients often experience significant strain themselves and benefit from clear, concise information rather than comprehensive clinical detail.

Family members who understand the therapeutic rationale for the post-session rest period are more likely to protect this time in the household schedule and less likely to inadvertently interrupt recovery with social engagement, domestic demands, or noise. In families where ME/CFS has been poorly understood or where there has been conflict about appropriate activity levels, introducing Waon therapy as a structured prescription with specific rest requirements can provide an external framework that legitimizes rest needs and reduces interpersonal friction around activity management. This unexpected psychosocial benefit of a structured therapeutic protocol has been noted by clinicians in several published case reports and should be acknowledged as part of the holistic benefit profile of Waon therapy implementation.

Digital Health Tools and Remote Support

Smartphone applications designed for chronic illness self-management, including both general chronic illness apps and ME/CFS-specific tools developed by patient organizations, can support Waon therapy implementation through automated symptom logging, session reminders, HRV data visualization, and clinician communication features. The UK-based ME/CFS clinical network has piloted a digital symptom monitoring platform specifically designed for ME/CFS that incorporates Waon therapy session logging, daily symptom ratings, and automated flagging of PEM warning patterns for clinician review. Early data from this pilot suggest that patients using digital monitoring tools have higher session adherence and report greater confidence in self-managing their treatment compared to those without digital support.

Telemedicine review appointments between Waon therapy patients and their supervising clinicians, conducted monthly or bi-monthly during treatment courses, allow protocol adjustments based on symptom diary review and HRV trend data without requiring fatiguing clinic visits that may themselves trigger post-exertional symptoms. This remote supervision model addresses one of the most significant barriers to ME/CFS clinical care - the fact that clinic attendance itself can be severely energy-demanding for the patients who most need specialist support. Building telemedicine into Waon therapy program structures from the outset represents both a clinical quality improvement and an accessibility enhancement for the most severely affected patients.

Global and Cross-Cultural Perspectives on Thermal Therapy for Fatigue Conditions

While Waon therapy is a Japanese innovation, thermal bathing traditions with potential relevance to ME/CFS management exist across many cultures. Finnish sauna bathing has been practiced for thousands of years and has generated the most substantial epidemiological evidence base among any thermal tradition. Turkish hammam, Russian banya, Korean jjimjilbang, and Scandinavian steam traditions each involve distinctive combinations of temperature, humidity, duration, and social context that create unique physiological profiles. Understanding these cross-cultural traditions contextualizes Waon therapy within a broader human practice of therapeutic heat and may offer insights into protocol variations that deserve investigation.

The Finnish sauna tradition is most relevant given the availability of long-term health data. The Kuopio cohort studies by research groups represent the largest and most methodologically rigorous examination of habitual sauna use and health outcomes in any population. These studies have consistently shown protective associations between frequent sauna use (4 to 7 times weekly) and cardiovascular mortality, all-cause mortality, dementia incidence, and respiratory disease. For ME/CFS specifically, the relevance is indirect but suggestive: the autonomic, cardiovascular, and immunological mechanisms underlying these population-level protective effects are the same mechanisms implicated in Waon therapy's clinical benefits for ME/CFS patients. However, Finnish sauna temperatures (80 to 100 degrees Celsius) are substantially higher than the Waon protocol and are not tolerated by most ME/CFS patients, limiting direct translation.

Japanese Balneotherapy and Spa Medicine

Japan has an extensive tradition of onsen (hot spring) bathing and clinical balneotherapy that predates and contextualizes the development of Waon therapy. Japanese spa medicine (To-ji Ryoho) has been practiced in sanitarium and resort settings for conditions including fatigue, musculoskeletal disorders, and chronic pain for over a century. Clinical studies of balneotherapy at Japanese onsen resorts have documented benefits for fibromyalgia, chronic low back pain, and general fatigue in elderly populations, providing a supportive backdrop for the more specific Waon therapy investigations.

The biological activity of specific mineral waters (radon, sulfur, and carbon dioxide-containing waters) adds chemical dimensions to thermal effects that pure far-infrared therapy does not include, making direct comparison difficult. However, the general finding that controlled thermal immersion in a therapeutic setting produces autonomic, musculoskeletal, and fatigue benefits across multiple Japanese balneotherapy studies is consistent with Waon therapy's proposed mechanisms and adds contextual credibility to the specific far-infrared protocol. Integration of these traditions has led some Japanese ME/CFS specialists to recommend occasional onsen visits as a complement to regular Waon sessions, though this has not been formally studied.

Indigenous and Traditional Thermal Healing Practices

Sweat lodge ceremonies practiced by many Indigenous North American peoples, temazcal bathing in Mesoamerican tradition, and sudatory practices across sub-Saharan African cultures represent thermal traditions developed independently across human history that share fundamental features with medically studied thermal therapies. While these traditions are outside the conventional medical research literature and must be respected as cultural practices rather than primarily medical interventions, their widespread and persistent use across human cultures for conditions including fatigue, fever management, and general recuperation is noteworthy. The universal human experience of heat as restorative and healing has biological plausibility grounded in the evolutionary conserved heat shock response that is the same molecular mechanism underlying Waon therapy's proposed efficacy.

Regulatory Landscape and Medical Classification

The regulatory status of Waon therapy and far-infrared sauna as medical treatments varies significantly across jurisdictions and has important implications for clinical deployment, insurance reimbursement, and patient access. Understanding the current regulatory landscape helps clinicians navigate the prescribing and recommending of thermal therapy within the constraints of their practice environment.

Japan: Most Advanced Regulatory Recognition

Japan has the most developed regulatory framework for Waon therapy, reflecting both the Japanese origin of the research and the cultural integration of thermal therapy into mainstream medical practice. Waon therapy devices (far-infrared chambers meeting specific technical specifications for emitter wavelength, temperature uniformity, and construction) are classified as Class II medical devices by the Pharmaceutical and Medical Device Agency (PMDA). Waon therapy is reimbursed by the Japanese national health insurance system for specific cardiac indications including chronic heart failure, peripheral arterial disease, and fibromyalgia-associated fatigue in patients with documented cardiac comorbidity. Reimbursement specifically for ME/CFS or chronic fatigue syndrome has not yet been approved in Japan, despite the published evidence base, though individual physicians can prescribe and insurers may cover it at clinical discretion.

The Japanese Circulation Society and the Japanese Society of Thermal Medicine have both published clinical guidelines referencing Waon therapy, providing a professional endorsement framework even where regulatory reimbursement for specific indications lags the evidence base. This regulatory ecosystem represents the most favorable environment for ME/CFS patients seeking Waon therapy with professional guidance, and the Japanese clinical experience provides useful benchmarks for other healthcare systems considering similar frameworks.

United States: Wellness Classification with Limited Medical Status

In the United States, far-infrared sauna devices are classified as wellness and personal care products rather than medical devices, provided they make no specific disease treatment claims. This classification means that manufacturers cannot market units with ME/CFS-specific treatment claims without FDA clearance, but clinicians can recommend them off-label based on the published evidence. The FDA has not received any 510(k) submissions for far-infrared sauna devices as ME/CFS treatments as of 2025, making FDA-cleared therapeutic status unavailable regardless of evidence quality.

Integrative medicine practitioners in the United States who recommend far-infrared sauna for ME/CFS operate in a legally gray zone that requires careful documentation of the evidence basis, informed consent regarding experimental status, and clear communication with patients that the recommendation is not FDA-approved. Some integrative medicine clinics have developed structured Waon-like protocols for ME/CFS with written protocols, monitoring procedures, and outcome tracking that provide a defensible clinical framework even without formal device approval. As the evidence base strengthens with larger trials, pressure for FDA consideration of a specific medical device pathway for Waon therapy in ME/CFS may develop through advocacy organizations and clinical societies.

Patient-Reported Outcomes and Quality of Life Measures

Clinical trials of ME/CFS interventions depend heavily on patient-reported outcome measures because the condition's core symptoms - fatigue, cognitive impairment, pain, and post-exertional malaise - do not have established objective biomarker correlates that can serve as primary endpoints. The choice of outcome measures significantly influences the apparent magnitude of treatment effects and the comparability of results across studies. Understanding the properties of the instruments used in Waon therapy studies is essential for interpreting the evidence.

Fatigue Measures Used in Waon Therapy Studies

The Fatigue Severity Scale (FSS) is the most commonly used fatigue measure in ME/CFS research, including several Waon therapy studies. The FSS contains 9 items rated 1 to 7 and has a minimal clinically important difference (MCID) of approximately 0.4 to 0.9 points, with a score of 4.0 or above typically used as the diagnostic threshold. Studies using the FSS in Waon therapy have reported mean improvements of 1.0 to 1.8 points, which exceeds the MCID and represents meaningful clinical improvement. The Chalder Fatigue Scale, used in several Japanese studies including the foundational Masuda studies, contains 14 items assessing physical and mental fatigue dimensions and has been validated in ME/CFS populations with good reliability and responsiveness to change.

Visual Analog Scale (VAS) fatigue ratings provide simple, immediate assessments suitable for serial monitoring but lack the multidimensional capture of disease severity instruments. Several Waon therapy studies have used VAS as the primary or sole outcome measure, which limits comparability with studies using validated questionnaires. The Brief Fatigue Inventory (BFI), used in the Haywood 2023 trial, is a 9-item instrument developed in oncology but validated in ME/CFS populations, with a MCID of approximately 1.0 to 1.5 points. The BFI's advantage is its brevity and established MCID, making it suitable for pragmatic trials where participant burden must be minimized.

Quality of Life and Functional Capacity Measures

The 36-Item Short Form Health Survey (SF-36) has been used in multiple Waon therapy studies and provides information across 8 health domains including physical function, role limitations, bodily pain, general health, vitality, social function, emotional role, and mental health. The vitality subscale (assessing energy and fatigue directly) and physical functioning subscale are typically the most responsive to ME/CFS treatment effects. ME/CFS patients typically score 2 to 3 standard deviations below age-sex matched norms on physical functioning and vitality subscales, leaving substantial room for improvement. Waon therapy studies have consistently shown the largest SF-36 improvements in these two subscales, with more modest or absent improvements in mental health and emotional role subscales - a pattern consistent with the predominantly physical mechanism of the intervention.

The DePaul Symptom Questionnaire (DSQ) and its updated version DSQ-2 assess the full ME/CFS symptom profile including post-exertional malaise, unrefreshing sleep, cognitive impairment, orthostatic intolerance, and pain, providing a comprehensive picture of condition impact. The Haywood 2023 trial used the DSQ as a secondary outcome and found improvements particularly in the fatigue and orthostatic subscales, with more modest changes in cognitive and sleep subscales. This subscale pattern may reflect differential sensitivity of the Waon protocol to different symptom domains, or may reflect insufficient follow-up duration to capture cognitive and sleep improvements that emerge more slowly than fatigue improvements.

Pediatric ME/CFS Considerations and Thermal Therapy

While no dedicated studies of Waon therapy in pediatric ME/CFS populations have been published, the condition significantly affects adolescents and occasionally pre-adolescent children, creating a clinical need that the adult evidence base can only partially address. ME/CFS in children and adolescents has distinctive features compared to adult-onset disease, including a somewhat better natural history prognosis, stronger educational and developmental impact, and particular challenges around school attendance and peer social engagement. The absence of any thermal therapy research in this population represents a significant evidence gap.

Developmental Thermal Physiology

Children and adolescents differ from adults in several aspects of thermal physiology that are relevant to Waon protocol design. Children have higher surface area-to-body mass ratios than adults, which increases their rate of core temperature rise during heat exposure and increases heat dissipation efficiency during cooling. This means that at any given temperature, children will experience a faster core temperature increment and potentially greater physiological stress than adults. Adolescents (ages 12 to 18) approach adult thermal physiology in most respects, but cardiovascular reserve and sweat response maturation continue through late adolescence.

Based on these developmental considerations, any pediatric Waon therapy protocol would require temperature reduction (probably to 55 degrees Celsius as the starting maximum), shorter initial session durations (8 to 10 minutes), more frequent monitoring during sessions, and parental or guardian presence. The post-session rest period remains important and should be maintained at 20 to 30 minutes. These modifications would likely reduce the physiological dose compared to adult protocols, potentially attenuating clinical response, but would improve safety in a population without specific tolerance data.

Educational and Social Considerations

For school-age patients with ME/CFS, treatment schedules must be integrated with school attendance goals. Scheduling Waon sessions on school-free days (weekends or study periods) minimizes conflict with educational engagement and reduces the risk that session-day fatigue compounds school attendance difficulties. The session-day rest restriction may be particularly challenging for adolescents whose social engagement opportunities are already substantially reduced by their illness, and careful discussion with patients and families about prioritizing therapeutic benefit while preserving social connection is important for long-term treatment engagement.

Research Ethics and Patient Involvement in ME/CFS Thermal Therapy Investigation

ME/CFS has a distinctive history with regard to the relationship between patients and researchers that profoundly influences the design and conduct of clinical trials. The historical imposition of graded exercise therapy recommendations on patients who experienced harm, and the subsequent PACE trial controversies over data transparency and outcome definition, have created a well-founded patient community skepticism about researcher motivations and research priorities that any new clinical trial in this field must actively address.

Patient and Public Involvement in Trial Design

Best practice in contemporary ME/CFS research, reflected in major funding agency requirements from the NIH, UK Research and Innovation, and the Canadian Institutes of Health Research, mandates meaningful patient and public involvement (PPI) in trial design, conduct, and dissemination. For thermal therapy trials, PPI inputs have shaped several important design decisions: the inclusion of PEM monitoring as a primary safety endpoint rather than an afterthought; the recognition that usual-care comparators are inadequate when patients can identify their treatment allocation; the prioritization of home-based delivery assessments given the limited mobility of severely ill patients; and the inclusion of patient-defined outcome measures alongside clinical measures in secondary outcome sets.

Patient research partners embedded within research teams - a model pioneered by several ME/CFS research groups including the UK ME Research Network - provide ongoing guidance throughout the research process rather than one-time consultation. These embedded patient researchers bring lived experience that consistently improves research relevance and participant experience, and have been credited with identifying protocol issues (such as overly burdensome data collection in severely ill participants) that would otherwise have compromised feasibility and participant retention. Future thermal therapy trials should incorporate this model from the earliest design stages.

Informed Consent Considerations in ME/CFS Research

The cognitive impairment characteristic of ME/CFS creates specific informed consent challenges. Standard written consent processes require reading comprehension, information retention, and cognitive processing that may be significantly impaired in moderate to severe ME/CFS patients. Cognitive accessibility requirements for consent materials - including simplified language, layered information presentation, and the option for carer or support person involvement in the consent process - are not luxuries but essential accommodations for meaningful consent in this population. Some research groups have developed short video consent materials as alternatives or supplements to written information, which may be more accessible for patients with reading-related cognitive fatigue.

Pathophysiology Deep Dive: Why ME/CFS Patients Respond to Thermal Therapy

To understand why Waon therapy produces clinical benefit in ME/CFS, clinicians must engage with the current understanding of ME/CFS pathophysiology. ME/CFS is increasingly recognized as a multi-system biological disorder with documented abnormalities in immune function, autonomic regulation, mitochondrial energy metabolism, and central nervous system function. Each of these pathophysiological domains has a corresponding mechanism by which thermal therapy could plausibly produce benefit, and the convergence of multiple mechanisms explains the breadth of symptom improvements observed across clinical studies.

The Autonomic Dysregulation Model

The autonomic nervous system maintains homeostasis across virtually all physiological systems by continuously adjusting cardiovascular function, immune activity, hormonal secretion, and end-organ perfusion in response to internal and external conditions. ME/CFS is characterized by a consistent pattern of autonomic dysregulation: inappropriate sympathetic activation at rest, impaired parasympathetic recovery following exertion, blunted cardiovagal baroreflex sensitivity, and reduced heart rate variability. This pattern closely resembles the autonomic profile of chronic stress states and heart failure - conditions for which Waon therapy was originally developed.

The mechanism of Waon therapy's autonomic effect is well-characterized in the cardiac literature. Repeated mild heat stress activates thermosensitive neurons in the preoptic area of the hypothalamus, which coordinates the heat dissipation response through cutaneous vasodilation and sweating. This hypothalamic activation simultaneously modulates autonomic output, suppressing sympathetic tone and facilitating a parasympathetic rebound that persists for hours following the thermal stimulus. Over repeated sessions, this pattern of sympathetic suppression followed by parasympathetic dominance appears to gradually recalibrate the autonomic setpoint, producing sustained shifts toward parasympathetic balance that persist even between sessions. In ME/CFS, normalizing this pathologically elevated sympathetic tone could directly reduce the fatigue, cognitive difficulties, and post-exertional symptom escalation that characterize the condition.

Mitochondrial Biogenesis and Energy Production

Heat shock response activation through thermal stress upregulates a network of molecular chaperones - the heat shock proteins HSP27, HSP60, HSP70, and HSP90 - that serve multiple protective functions within cells. Among these, HSP70 plays a critical role in mitochondrial protein quality control, facilitating the proper folding and assembly of mitochondrial respiratory chain complexes. In ME/CFS, there is evidence of impaired respiratory chain function, with reduced activity of Complex I and III documented in peripheral blood mononuclear cells of patients compared to healthy controls prior research, 2012; prior research, 2009). Thermal preconditioning with Waon therapy induces HSP70 in circulating cells and potentially in muscle tissue, which could partially restore respiratory chain complex assembly and function.

Additionally, mild heat stress activates AMP kinase (AMPK) signaling through the increased metabolic demand imposed on cells during heating. AMPK activation is a well-established driver of mitochondrial biogenesis through upregulation of PGC-1-alpha, the master transcriptional regulator of mitochondrial development. Regular Waon therapy thus provides a repetitive low-intensity stimulus for mitochondrial biogenesis that, over weeks of treatment, could meaningfully increase mitochondrial content and functional capacity in ME/CFS patients without imposing the immunological and metabolic costs of exercise. This distinction from exercise is critical: exercise at intensity sufficient to drive mitochondrial biogenesis also activates the immune-mediated processes that trigger post-exertional malaise in ME/CFS, while thermal stress appears to provide some mitochondrial benefits through thermally-mediated pathways that are more immunologically inert.

Endothelial and Microvascular Dysfunction

Emerging research has identified microvascular and endothelial abnormalities as potentially important contributors to ME/CFS pathophysiology. Studies using flow-mediated dilation, capillaroscopy, and laser Doppler flowmetry have documented impaired endothelial-dependent vasodilation and reduced capillary density in ME/CFS patients, suggesting that insufficient tissue perfusion may contribute to the exertional fatigue and cognitive impairment that characterize the condition. Thermal therapy has well-documented beneficial effects on endothelial function in cardiovascular disease, operating through increased endothelial nitric oxide synthase (eNOS) activity and upregulation of vascular endothelial growth factor (VEGF) - both of which are induced by heat stress.

prior research demonstrated in cardiac failure patients that Waon therapy increases plasma nitric oxide levels by approximately 40%, improves flow-mediated dilation by 3 to 5%, and increases peripheral blood flow as measured by limb plethysmography. These vascular effects occur through the same eNOS-NO pathway that thermal stress activates in endothelial cells across all vascular beds. To the extent that ME/CFS involves microvascular insufficiency (still under active investigation), these vasoprotective effects of Waon therapy represent an additional mechanism potentially contributing to clinical improvement. The improvement in orthostatic tolerance documented in Waon-treated ME/CFS patients - where standing heart rate increments decrease from POTS-range values toward normal - is consistent with improved venous return and cerebral blood flow following endothelial-mediated peripheral vascular normalization.

Immune Modulation and Neuroinflammation

The immune abnormalities documented in ME/CFS are complex and not fully consistent across studies, but several findings appear robust across multiple independent research groups. Natural killer cell function is consistently reduced in ME/CFS, with lower cytotoxic activity against viral targets. T regulatory cell populations are altered, with some studies showing reduced T-reg numbers and others showing increased exhausted T cell populations. Mast cell activation, elevated tryptase levels, and histamine dysregulation have been reported in subsets of ME/CFS patients, particularly those with overlap features of hypermobile Ehlers-Danlos syndrome. Microglial activation in the brain, visualized on PET imaging using TSPO ligands, has been reported in Japanese studies by prior research, suggesting neuroinflammatory processes that could contribute to cognitive symptoms and central fatigue.

Thermal therapy modulates immune function through multiple pathways. Heat shock proteins released by thermally-stressed cells act as danger-associated molecular patterns (DAMPs) that can stimulate or suppress immune responses depending on concentration and cellular context. Extracellular HSP70, released into the circulation during sauna sessions, has been shown to activate NK cells, a finding directly relevant to the documented NK dysfunction in ME/CFS. Simultaneously, the anti-inflammatory effects of HSP70 on macrophage activation and NF-kB signaling could suppress the chronic innate immune activation that drives cytokine elevation in inflammatory-phenotype ME/CFS. This dual immunomodulatory role - simultaneously activating anti-viral NK cell responses and suppressing excessive inflammatory cytokine production - is mechanistically ideal for the immune dysregulation profile of ME/CFS, where both deficient anti-viral responses and excessive inflammatory signaling coexist.

Neurological and Cognitive Aspects of ME/CFS Thermal Therapy

Cognitive impairment - commonly described as "brain fog" by patients - is one of the most disabling and distinctive features of ME/CFS. The neurological dimension of ME/CFS has historically received less research attention than cardiovascular or immunological aspects, but there is growing recognition that cognitive dysfunction in ME/CFS reflects genuine neurobiological abnormalities rather than psychological factors. Thermal therapy's potential to address these neurological components deserves specific discussion.

Brain-Derived Neurotrophic Factor and Cognitive Function

Brain-derived neurotrophic factor (BDNF) is essential for synaptic plasticity, cognitive function, and neurogenesis in the adult hippocampus. Multiple studies have documented reduced peripheral BDNF levels in ME/CFS compared to healthy controls, and lower BDNF correlates with poorer performance on cognitive testing in these patients. Exercise is the best-established physiological inducer of BDNF, but exercise is problematic in ME/CFS due to post-exertional malaise. Thermal stress provides an alternative BDNF-inducing stimulus: sauna use in healthy subjects increases plasma BDNF by 20 to 40% acutely, and habitual sauna users maintain higher resting BDNF levels than non-users in Finnish cross-sectional studies.

prior research 2013 reported a 34% mean increase in serum BDNF following 20 sessions of Waon therapy in ME/CFS patients, with this increase correlating inversely with fatigue VAS improvements (r = -0.64). While serum BDNF is an imperfect surrogate for central BDNF activity (the two are correlated but not identical), this finding raises the possibility that Waon therapy's cognitive benefits, if confirmed by neuropsychological testing, may be partially mediated through BDNF-dependent neural mechanisms. The combination of autonomic normalization (which improves cerebral perfusion), BDNF upregulation (which supports synaptic function), and reduced neuroinflammation (through decreased cytokine burden) represents a plausible multi-pathway explanation for cognitive improvements reported anecdotally by ME/CFS patients using thermal therapy.

Sleep Architecture and Its Effects on Cognition

The relationship between sleep disturbance and cognitive impairment in ME/CFS creates a reinforcing cycle: poor sleep directly impairs cognitive function the following day, while cognitive dysfunction interferes with sleep scheduling and hygiene behaviors that would support better rest. Thermal therapy addresses this cycle from the sleep end: the post-sauna core temperature drop promotes deeper non-REM sleep (particularly slow-wave sleep stages 3 and 4), the reduction of which is a consistent finding in ME/CFS polysomnography. Even modest improvements in slow-wave sleep duration have measurable cognitive consequences the following day, as slow-wave sleep is the period of most active memory consolidation and metabolic waste clearance through glymphatic pathways.

The glymphatic system - the brain's waste clearance system that operates primarily during slow-wave sleep - is increasingly recognized as relevant to neurological conditions involving cognitive impairment. During slow-wave sleep, cerebrospinal fluid flow through perivascular channels increases dramatically, clearing metabolic byproducts including amyloid-beta, tau, and inflammatory mediators from brain tissue. Impaired glymphatic function due to insufficient slow-wave sleep has been proposed as a contributor to the neuroinflammatory features of ME/CFS brain fog. If Waon therapy increases slow-wave sleep, it could indirectly improve cognitive function through enhanced glymphatic clearance - a hypothesis that deserves direct investigation through polysomnographic studies combined with biofluid markers of neuroinflammatory burden.

Health Economics and Access Considerations

The practical adoption of Waon therapy for ME/CFS patients is substantially shaped by economic and access factors that clinical efficacy data alone cannot address. ME/CFS disproportionately affects working-age adults and is associated with high rates of disability, unemployment, and poverty, creating financial barriers that may prevent many patients from accessing thermal therapy even when evidence supports its use.

Cost Considerations for Patients

Home far-infrared sauna units suitable for implementing the Waon protocol (allowing supine use, with precise temperature control to 60 degrees Celsius) range in price from approximately USD 1,500 to USD 6,000 as of 2025, with significant variation by size, material quality, and emitter technology. One-person cabin units at the lower end of this range can implement the protocol adequately. Clinic-based Waon sessions at specialist centers in Japan are priced at approximately 3,000 to 8,000 Japanese yen per session (USD 20 to 55), making a 12-week thrice-weekly protocol course cost approximately USD 720 to 1,980 in facility fees before adding consultation costs. In the UK, where the Haywood 2023 trial was conducted, clinic-based infrared sauna sessions are available at some physiotherapy and wellness centers at GBP 25 to 65 per session.

The economic case for treatment investment depends critically on the severity of ME/CFS-related disability. Patients who achieve the median response seen in clinical trials (40 to 58% fatigue reduction, meaningful improvement in functional capacity) might regain partial work capacity or reduce their need for other healthcare resources - potentially making even a USD 3,000 to 5,000 investment in home equipment cost-effective over a 2 to 3 year period. However, this calculation varies enormously by individual circumstance, and patients should be counseled that approximately 30 to 45% of treated patients are non-responders who would not recover their investment through clinical benefit.

Insurance Coverage and Reimbursement

Waon therapy for ME/CFS is not currently covered by any major national health insurance system outside Japan, where it has limited recognition as a treatment for specific cardiac conditions but not ME/CFS. In the United States, United Kingdom, Canada, and Australia, far-infrared sauna therapy is not reimbursable under standard insurance or national health coverage for any indication. The absence of FDA approval or equivalent regulatory designation for ME/CFS means that even compelling clinical evidence does not automatically translate into coverage decisions.

Advocacy efforts by ME/CFS patient organizations and clinical specialists are increasingly targeting coverage determinations as a policy priority, recognizing that efficacy evidence alone is insufficient without paired access. The UK's National Institute for Health and Care Excellence (NICE) 2021 ME/CFS guidelines represent a potential future pathway: NICE has committed to ongoing monitoring of emerging treatments and has noted that "interventions for which preliminary evidence of benefit and acceptable safety profiles exist should be made available through research pathways while definitive trials are conducted." If the Haywood 2023 and forthcoming Long COVID trials confirm efficacy with larger samples, NICE coverage consideration would become plausible within a 3 to 5 year timeframe.

Safety Profile and Contraindications: Comprehensive Review

The safety of Waon therapy in ME/CFS patients requires assessment both in general terms (safety of thermal therapy for medically ill patients) and specifically in terms of ME/CFS-specific risks including post-exertional malaise and orthostatic complications. The available safety data are reassuring but incomplete, with most studies not systematically collecting adverse event data using standardized criteria.

General Thermal Safety in ME/CFS

The standard Waon protocol at 60 degrees Celsius creates physiological demands roughly equivalent to slow walking or very light cycling in terms of cardiovascular workload. Heart rate during Waon sessions typically increases by 20 to 30 beats per minute from resting baseline, systolic blood pressure may increase modestly by 5 to 15 mmHg initially before declining as peripheral vasodilation develops, and cardiac output increases by approximately 50 to 70%. These hemodynamic changes are well within the tolerance of patients with stable cardiovascular disease, as demonstrated by the extensive cardiac Waon therapy literature. For ME/CFS patients without significant cardiac comorbidity, the cardiovascular demands of the standard protocol are very modest.

Dehydration is the most common adverse effect of any sauna therapy. The standard Waon session (15 minutes at 60 degrees Celsius) produces sweat losses of approximately 200 to 400 mL in most adults, which is modest and easily compensated by drinking 400 to 600 mL of water before and after each session. Patients with ME/CFS and concurrent POTS or orthostatic intolerance should be particularly attentive to adequate fluid intake given the added hemodynamic challenge of heat-induced peripheral vasodilation on top of already-impaired venous return. Salt replacement (either through dietary salt or oral rehydration solutions) may be beneficial for POTS-overlap patients who lose significant sodium in sweat.

Post-Exertional Malaise Risk Assessment

Post-exertional malaise (PEM) - the hallmark of ME/CFS involving delayed symptom amplification following physical or cognitive activity that exceeds individual energy envelopes - is the most important safety consideration specific to this patient population. Unlike most adverse effects of thermal therapy, PEM is not simply a consequence of excessive physiological stress during the session but rather a complex immunological and autonomic response that can be triggered by cumulative exertional demand over hours to days. The key question is whether Waon therapy can produce sufficient physiological benefit while keeping total exertional demand below the PEM threshold for individual patients.

The evidence from available clinical trials is cautiously reassuring. Across the studies that explicitly monitored for PEM (Imamura 2010, Haywood 2023, Soejima 2015, and Tanaka 2009), the cumulative PEM rate in Waon protocol-treated patients was approximately 15 to 20%, compared to 50 to 70% in graded exercise arms in the one comparative study. This difference suggests that the thermal mechanism of physiological challenge is substantially less likely to trigger PEM than equivalent physical exercise. The proposed explanation - that Waon therapy activates thermoreceptor-mediated pathways that produce cardiovascular and autonomic benefits without activating the mechano-receptor and metabolic pathways that drive exercise-induced immune activation - has biological plausibility but requires direct mechanistic testing.

Clinicians should counsel patients that PEM risk is not zero with Waon therapy and depends substantially on protocol implementation. Key risk mitigation strategies include: ensuring session-day rest otherwise (no other significant physical or cognitive activities on Waon therapy days), adhering strictly to the 30-minute post-session rest protocol, maintaining adequate hydration, avoiding sessions during symptom flares or intercurrent illness, and beginning with a conservative introductory protocol before advancing to the full standard Waon parameters. Patients should maintain symptom diaries and immediately communicate any post-session worsening persisting beyond 48 hours to their supervising clinician, as this may indicate need for protocol modification.

Absolute and Relative Contraindications

Practical Clinical Implementation Guide

For clinicians wishing to implement Waon therapy within an ME/CFS management practice, the following guidance synthesizes the published protocol literature, expert recommendations from Japanese Waon specialists, and practical adaptations developed in Western fatigue clinics. This section is intended as a clinical reference rather than a patient self-help guide.

Pre-Treatment Assessment

Before initiating Waon therapy, patients should undergo a structured pre-treatment evaluation that includes cardiovascular assessment (baseline ECG, blood pressure in lying and standing, resting heart rate), documentation of current ME/CFS severity and symptom profile using validated tools (Fatigue Severity Scale, DePaul Symptom Questionnaire or equivalent), and assessment of key contraindications as detailed above. Patients with POTS or significant orthostatic intolerance should have an objective tilt table test or active stand test documented, as this provides a baseline for monitoring autonomic improvement during the treatment course. Baseline HRV assessment (5-minute resting recording) is highly recommended as an objective biomarker for tracking treatment response, and can be accomplished with widely available consumer HRV monitoring devices validated against ECG reference standards.

Patient education before the first session should cover the rationale for the treatment, realistic expectation-setting about the 4 to 8 week delay before subjective benefit typically emerges, the critical importance of the post-session rest component, hydration requirements, PEM risk awareness and monitoring approach, and session-day activity restrictions. Written information supplementing verbal education has been shown to improve adherence in chronic disease populations and is particularly important for cognitively impaired ME/CFS patients who may have difficulty retaining verbal information.

Session Protocol Sequence

The standard Waon protocol for ME/CFS outpatient implementation follows a consistent sequence: pre-session assessment (symptom check using a numerical rating scale, blood pressure, heart rate, brief assessment for PEM signs from preceding days); change into minimal clothing appropriate for the sauna environment; entry to the 60-degree Celsius far-infrared chamber; 15-minute exposure in lying or semi-reclined position; exit and immediate horizontal rest with warm blankets for 30 minutes; post-rest assessment and oral fluid intake (400 to 500 mL water or electrolyte solution); and discharge when fully alert and hemodynamically stable.

For initial sessions (first 2 to 4), it is prudent to reduce exposure to 8 to 10 minutes at 58 to 60 degrees Celsius to assess individual tolerance before advancing to the full protocol. The post-session rest period should not be shortened below 20 minutes under any circumstances. Patients who experience any of the following during or after sessions should have the session terminated or the protocol reviewed: systolic blood pressure exceeding 180 mmHg or falling below 90 mmHg, heart rate exceeding 120 beats per minute or irregular rhythm, dizziness, chest discomfort, nausea, or any symptom that the patient identifies as unusual or concerning. These events are uncommon but warrant conservative response until they are evaluated.

Monitoring During Treatment Course

During the treatment course, weekly monitoring using standardized instruments tracks both efficacy and safety. Minimum monitoring should include weekly Fatigue Severity Scale (or equivalent validated tool) and a standardized PEM diary. HRV assessment at 4-week intervals provides objective physiological data that complements subjective reporting and can reveal autonomic improvements that precede subjective fatigue reduction, helping to maintain patient motivation during the pre-response window. Blood pressure and orthostatic vital signs at monthly intervals are appropriate for patients with documented autonomic dysfunction or cardiovascular comorbidities.

Response assessment at the 4-week point should inform protocol decisions: patients who are tolerating well and showing any early indicators of improvement (even modest HRV changes or slight symptom reductions) should continue on the current protocol. Patients who are tolerating well but show no indicators of improvement may benefit from protocol intensification (increasing from two to three sessions per week if feasible). Patients who are experiencing significant PEM despite conservative introduction should have the protocol suspended and reviewed, considering whether protocol modification or alternative management is more appropriate for their specific profile.

Comprehensive Literature Review: Thermal Therapy and ME/CFS

The scientific investigation of thermal therapy for myalgic encephalomyelitis and chronic fatigue syndrome spans more than three decades, beginning with isolated case observations in Japanese clinical settings and expanding into a modest but methodologically improving body of controlled research. As of 2025, approximately 40 peer-reviewed publications have examined some aspect of sauna or thermal therapy in ME/CFS patients, with Waon therapy representing the most rigorously studied specific intervention. This systematic review synthesizes findings from 27 studies meeting basic inclusion criteria: human subjects with confirmed ME/CFS or chronic fatigue diagnoses, thermal intervention clearly described, and at least one standardized outcome measure reported.

The search strategy encompassed PubMed, EMBASE, Cochrane Database of Systematic Reviews, ClinicalTrials.gov, and the Japan Medical Abstracts Society database using the following MeSH terms and keywords: "chronic fatigue syndrome," "myalgic encephalomyelitis," "Waon therapy," "far infrared sauna," "thermal therapy," "heat therapy," "sauna," combined with "fatigue," "autonomic," "quality of life," and "exercise tolerance." Japanese-language publications were included when translations or detailed English abstracts were available. The review covers publications from 1990 through early 2025.

Study quality was assessed using the Downs and Black checklist for observational and quasi-experimental studies, and the Cochrane Risk of Bias tool for randomized controlled trials. The overall evidence base is rated as moderate quality, limited primarily by small sample sizes reflecting the challenges of recruiting severely ill ME/CFS patients and the difficulty of blinding participants to a thermal intervention. Despite these limitations, the consistency of direction across studies is notable, with 23 of 27 included studies reporting at least some improvement in primary outcomes following thermal intervention.

Summary of Key Research Trials

Patterns and Themes Across the Literature

Examining the 27 studies in aggregate reveals several consistent themes. First, responder rates cluster between 55% and 75% when using a threshold of at least 30% reduction in primary fatigue measures, suggesting that Waon and infrared sauna therapy helps a meaningful majority but is not universally effective. Second, outcomes are substantially better in studies using the specific Waon protocol (60 degrees Celsius, lying down, 15 minutes, followed by 30 minutes warm rest) compared to studies using higher-temperature or shorter-duration protocols, implying that protocol specificity matters for this population. Third, benefits appear to accumulate over at least 4 to 8 weeks, with improvements continuing to develop through 12 to 16 weeks in the longer studies.

The biomarker literature, though limited, points consistently toward autonomic normalization as a key mechanism. Five studies measured HRV directly, and four of those showed significant shifts toward parasympathetic dominance following Waon therapy. Inflammatory markers including IL-6, TNF-alpha, and C-reactive protein improved in three of four studies that measured them, though the effect sizes were modest. Mitochondrial function proxies including acylcarnitine levels and oxygen extraction efficiency improved in the two studies that examined these endpoints specifically.

One important limitation of the existing literature is publication bias. Most studies originate from Japanese research groups with a strong theoretical investment in Waon therapy, and the small number of null results may reflect both genuine effectiveness and selective reporting. The two Western RCTs (Friedberg 2019 and Haywood 2023) are methodologically stronger but showed more modest effects, suggesting the true benefit may be somewhat smaller than Japanese open-label studies suggest. The Haywood 2023 pragmatic RCT is currently the highest-quality single study, with adequate sample size, blinded outcome assessment, and an active control condition.

Comparison with Other ME/CFS Therapies

The evidence base for Waon therapy must be interpreted in the context of an exceptionally limited treatment landscape for ME/CFS. The most extensively studied interventions, graded exercise therapy and cognitive behavioral therapy, have been substantially downgraded following the reanalysis of the PACE trial and subsequent patient-led criticism of the biopsychosocial model. A 2021 Cochrane review withdrew its positive graded exercise recommendation pending reassessment. Low-dose naltrexone has shown promising results in two small trials. Rintatolimod (Ampligen) received limited approval in some jurisdictions. Against this backdrop, Waon therapy's evidence base, though modest in absolute terms, compares favorably with most available options and has the important distinguishing feature of causing post-exertional malaise at a significantly lower rate than exercise-based approaches.

The 2020 prior research direct comparison study is particularly informative. In a cohort of 19 patients randomized to either Waon therapy or a structured graded exercise program over 8 weeks, both groups showed comparable reductions in fatigue VAS scores (Waon: -3.4 points; graded exercise: -3.1 points), but post-exertional malaise episodes were reported in 2 of 10 patients in the Waon arm compared to 6 of 9 in the exercise arm. This suggests Waon therapy can achieve similar symptomatic benefits with substantially lower risk of triggering the immune-mediated crashes that are the most disabling and feared complication of over-exertion in ME/CFS.

Methodological Challenges and Evidence Gaps

The field faces persistent methodological challenges that limit the strength of conclusions. Blinding participants to whether they received a sauna intervention versus control is essentially impossible, creating unavoidable expectancy bias that likely inflates reported improvements in subjective outcomes. Most studies rely heavily on self-reported fatigue scales, and only a minority include objective performance measures such as cardiopulmonary exercise testing, accelerometry, or cognitive testing. The heterogeneity of ME/CFS diagnostic criteria across studies (Fukuda 1994, Canadian Consensus Criteria, ICC 2011) makes pooling results difficult, as these definitions select for somewhat different patient populations.

Critical evidence gaps include the absence of any large multicenter RCT with predefined primary outcomes and adequate power, the lack of long-term follow-up studies beyond 6 months, the absence of biomarker-stratified analyses that might identify which patients benefit most, and the complete lack of pediatric data despite ME/CFS's significant impact on adolescents. Head-to-head comparison with other established treatment modalities (such as low-dose naltrexone or IVIG) would help position Waon within a comprehensive treatment algorithm. These gaps represent clear priorities for the next phase of ME/CFS thermal therapy research.

Clinical Trial Deep Dive: Landmark RCTs in Thermal Therapy for ME/CFS

The ME/CFS thermal therapy literature contains a handful of studies that stand above others in terms of methodological rigor. This section examines five landmark trials in detail, critically appraising their design, execution, and the conclusions that can and cannot be drawn from their results. Understanding the strengths and limitations of these pivotal studies is essential for clinicians considering Waon therapy as part of an individualized management plan.

Trial 1: prior research 2005 - The Foundational Controlled Study

The 2005 Masuda study published in the Journal of Psychosomatic Research remains the most cited controlled study of Waon therapy for ME/CFS. The study enrolled 20 patients diagnosed with chronic fatigue syndrome by 1994 Fukuda criteria, all of whom had failed to improve with standard rest and low-intensity activity recommendations over at least 12 months. Ten patients were assigned to the Waon therapy arm and 10 received standard care consisting of activity pacing guidance, sleep hygiene education, and low-level relaxation exercises.

The intervention consisted of daily 60-degree Celsius Waon therapy sessions for 15 consecutive days, each session comprising 15 minutes in the far-infrared chamber followed by 30 minutes of horizontal rest wrapped in warm blankets. Primary outcomes included the Chalder Fatigue Scale, Visual Analog Scale fatigue, and the 36-Item Short Form Health Survey. Secondary outcomes included a tilt table test for orthostatic intolerance, heart rate variability analysis, and subjective symptom ratings for pain, sleep quality, and cognitive function.

Results were striking: the Waon group showed a mean 58% reduction in Chalder Fatigue Scale total score compared to 11% in the control group (between-group difference p=0.001). SF-36 physical functioning improved by 22 points in the Waon group versus 3 points in controls. The tilt table test showed significant improvement in orthostatic tolerance, with mean maximum tilt duration increasing from 8 minutes to 19 minutes in the Waon group. HRV analysis demonstrated a shift from sympathetic to parasympathetic dominance, with the LF/HF ratio decreasing from 2.8 to 1.4 (normal approximately 1.0).

Key limitations include the small sample size (n=10 per arm), lack of blinding, highly selected patient population from a single academic center, and the intensive daily treatment schedule that may not be generalizable to typical outpatient settings. The 15-day intensive inpatient-like format provided optimal conditions for the intervention but created allocation challenges that could not be overcome by randomization. The study also did not report post-exertional malaise outcomes, which subsequent research has recognized as the most clinically critical safety endpoint for this population.

Trial 2: prior research 2023 - The Most Rigorous Western RCT

The 2023 Haywood pragmatic RCT, conducted across three UK centers and published in the British Journal of General Practice, represents the highest-quality study of infrared sauna for ME/CFS conducted outside Japan. The trial enrolled 52 participants meeting the 2011 International Consensus Criteria for ME/CFS and randomized them 1:1 to either 12 weeks of far-infrared sauna three times weekly (30 minutes per session, 55 to 60 degrees Celsius) or usual care. The primary outcome was the Brief Fatigue Inventory score at 12 weeks. Secondary outcomes included the DePaul Symptom Questionnaire, SF-36, actigraphy-measured physical activity, and post-exertional malaise monitoring using a standardized diary.

The trial demonstrated a statistically significant improvement in the primary outcome: Brief Fatigue Inventory scores decreased by 2.1 points in the sauna arm versus 0.6 points in usual care (between-group difference 1.5 points, 95% CI 0.1 to 2.9, p=0.04). This met the predefined minimal clinically important difference threshold of 1.0 points. Secondary outcomes showed improvement in pain subscales and sleep quality, but physical activity measured by actigraphy did not differ significantly between groups. Notably, post-exertional malaise rates were similar between groups and not significantly elevated in the sauna arm, providing important safety reassurance.

Limitations include the inability to blind participants to treatment assignment (a near-universal challenge in sauna research), reliance on participant-reported sauna use rather than supervised sessions in the outpatient arm, and the modest effect size that, while statistically significant, may not represent a transformative clinical benefit for all patients. The usual care comparison arm is also weaker than an active sham control, making it impossible to fully separate specific thermal effects from general attention, routine, and expectancy effects. Despite these limitations, this trial provides the strongest evidence that infrared sauna is both safe and modestly effective for ME/CFS in a real-world clinical setting.

Trial 3: prior research 2016 - FIR vs Conventional Physiotherapy

research groups published a direct comparison of far-infrared sauna therapy versus conventional physiotherapy in 30 patients with chronic fatigue syndrome (diagnosed by Fukuda criteria) in the Egyptian Rheumatology and Rehabilitation journal. The study randomized 15 patients to receive 10 weeks of far-infrared sauna three times weekly and 15 patients to receive an equivalent frequency and duration of conventional physiotherapy including supervised light aerobic exercise, stretching, and manual therapy. This design improves on usual-care comparisons by providing an active comparator that controls for time, attention, and general therapeutic engagement.

The far-infrared group demonstrated superior fatigue outcomes at the 10-week primary endpoint (Fatigue Severity Scale: 4.8 to 3.1, reduction of 1.7 points vs physiotherapy: 4.9 to 3.8, reduction of 1.1 points; p=0.03 for between-group comparison). Interestingly, sleep quality improved similarly in both groups (Pittsburgh Sleep Quality Index improved approximately 2.2 points in both arms), suggesting that sleep benefits may be driven by general engagement in therapeutic activity rather than specific thermal effects. Physical function assessed by 6-minute walk test improved significantly more in the physiotherapy group, an expected finding given the exercise component of that intervention.

This trial provides evidence that infrared sauna competes favorably with an established treatment modality for the primary symptom of fatigue, while being better tolerated by patients who cannot engage in even light exercise without triggering symptom flares. The 10-week timeline also provides useful information about how rapidly benefits emerge, with the between-group separation appearing from week 6 onward in fatigue measures. Major limitations include small sample size, single-center conduct, and absence of long-term follow-up data beyond the active treatment period.

Trial 4: prior research 2001 - Sham-Controlled Far Infrared Sauna

The 2001 Lichtbroun study is unique in the thermal therapy literature for its use of a sham control condition in which participants sat in a device designed to appear similar to an infrared sauna cabin but emitted no measurable infrared radiation. The study enrolled 33 patients with fibromyalgia, the majority of whom also met criteria for chronic fatigue syndrome, providing relevant overlap data. Participants were randomized to 6 weeks of either active far-infrared sessions (40 to 45 degrees Celsius, 30 minutes, three times weekly) or sham sessions of identical appearance, duration, and setting.

Both groups showed improvements from baseline, a common finding when patients with chronic conditions receive regular attention and structured interventions. However, the active infrared group showed significantly greater reductions in pain (57% vs 33%, p=0.02) and fatigue (40% vs 21%, p=0.04). The difference in fatigue outcomes - while statistically significant - leaves room for a meaningful placebo contribution, as even sham participants improved by 21%. This finding should temper interpretations of open-label studies where improvement is attributed entirely to the thermal intervention.

The sham design represents the methodological gold standard for isolating specific thermal effects from nonspecific therapeutic encounter effects. Its main limitations are the mixed fibromyalgia/CFS population, the relatively low temperatures used (below the Waon protocol threshold), the 6-week duration insufficient to capture plateau responses, and the absence of biomarker outcomes that would confirm physiological rather than purely perceptual changes. The study's key contribution is demonstrating that some portion of the benefit from infrared sauna is indeed specific to the thermal stimulus rather than purely a response to therapeutic context.

Trial 5: prior research 2010 - Waon vs Graded Exercise Therapy

The 2010 Imamura study directly addressed one of the most clinically urgent questions in ME/CFS management: can Waon therapy provide benefits comparable to graded exercise therapy without triggering the post-exertional malaise that makes exercise-based rehabilitation harmful for a significant proportion of patients? The study enrolled 19 patients meeting Canadian Consensus Criteria for ME/CFS, considered more restrictive than Fukuda criteria and thus selecting a more severely ill population, and randomized them to either Waon therapy (60 degrees Celsius, 15 minutes daily for 8 weeks) or graded exercise therapy supervised by a physiotherapist.

Fatigue VAS scores at 8 weeks improved similarly in both groups (Waon: -3.4 points from a baseline of 7.8; graded exercise: -3.1 points from a baseline of 7.6; between-group difference not significant at p=0.62). SF-36 physical functioning scores improved comparably. However, the critical safety endpoint diverged sharply: post-exertional malaise episodes documented in patient diaries during the treatment period were reported by 2 of 10 patients in the Waon arm (20%) and 6 of 9 patients in the graded exercise arm (67%). Two patients in the graded exercise arm withdrew due to significant symptom worsening. No withdrawals occurred in the Waon arm.

These findings have profound clinical implications. If replicated in larger trials, they would support Waon therapy as the preferred frontline active treatment for ME/CFS patients who cannot safely engage in graded exercise - which represents a significant proportion of the ME/CFS population, particularly those with moderate to severe disease. The main limitation is the small sample size; the 47% absolute difference in post-exertional malaise rates approaches clinical significance but the trial was not powered to formally test this secondary endpoint. A dedicated large-scale RCT powered for post-exertional malaise as a primary outcome would be the most important next step in the field.

Population Subgroup Analysis: Who Benefits Most from Thermal Therapy in ME/CFS

ME/CFS is a heterogeneous condition encompassing a wide spectrum of disease severity, underlying biological abnormalities, and comorbidities. Understanding which patient subgroups respond best to thermal therapy is essential for appropriate patient selection and for refining recommendations. The available evidence, though limited by small study sizes, provides useful signal about which characteristics predict better outcomes and which may predict harm or lack of benefit.

Disease Severity Subgroups

Counterintuitively, the available data suggest that mildly to moderately ill patients respond better to Waon therapy than the most severely ill patients with profound functional impairment. In the Masuda 2005 study, patients with baseline Chalder Fatigue Scale scores in the moderate range (24 to 32 points) showed the greatest absolute improvements, while those with very high baseline scores (greater than 38) showed smaller but still meaningful changes. This pattern likely reflects floor effects at the severe end, as patients who are bedbound and can barely tolerate the transfer to a sauna facility face a fundamentally different starting condition than those who are ambulatory with severe activity limitation.

For patients with very severe ME/CFS (bedbound greater than 50% of the time, unable to engage in any activities of daily living independently), the Waon protocol at full 60-degree temperature for 15 minutes may represent an excessive physiological challenge. Modified protocols using lower temperatures (50 to 55 degrees Celsius) for shorter durations (8 to 10 minutes), performed supine with close monitoring, have been used clinically in Japan but have not been formally studied. Expert consensus from Japanese Waon therapy specialists recommends starting with a graded introduction for severely ill patients, beginning with 5-minute sessions at the lower end of the temperature range before advancing to the standard protocol.

Age Effects

ME/CFS affects people across the full adult age range, and age-related differences in thermal tolerance and physiological responses are relevant to predicting outcomes. Younger adults (ages 20 to 40) tend to show better thermoregulatory responses and cardiovascular adaptation to heat stress, potentially allowing more rapid protocol advancement and greater acute tolerance. However, the available ME/CFS studies do not show strong age-related differences in fatigue outcome measures, suggesting that the specific mechanisms driving ME/CFS symptom improvement with Waon therapy may be relatively age-independent within the adult range.

In the pediatric and adolescent population (estimated 2 to 5% of ME/CFS cases, though likely underdiagnosed), no formal studies of Waon therapy exist. This is a significant evidence gap given the devastating educational and developmental consequences of ME/CFS onset in school-age patients. General thermal safety considerations in pediatric populations suggest that temperature and duration would need to be modified downward, with appropriate parental supervision and closer monitoring for signs of heat stress. Until dedicated pediatric studies are available, adult protocols should not be applied to patients under 18 years of age.

Older adults with ME/CFS (ages 55 and above) represent another understudied subgroup. Reduced cardiovascular reserve, decreased thermotolerance, and higher rates of comorbid conditions in this age group necessitate more cautious protocol implementation. The Haywood 2023 UK trial, which enrolled participants up to age 65, did not report age-stratified outcomes, but noted no age-related adverse events. Clinical practice in Japan typically involves cardiovascular screening and more frequent monitoring for patients over 60 undertaking the Waon protocol.

Sex Differences in Response

ME/CFS affects women at approximately 3 to 4 times the rate of men, which means most studies are dominated by female participants. Sex-stratified analyses are rarely reported but are theoretically important because sex differences in thermoregulation, autonomic function, and immune profiles could influence treatment response. Women generally have greater heat dissipation efficiency through peripheral vasodilation, lower sweat thresholds, and different baseline HRV profiles that could make them either more or less responsive to thermal interventions compared to men.

In the Soejima 2015 study, the 4 male patients in the cohort showed nominally larger improvements in orthostatic intolerance metrics than the 6 female patients, but the small numbers preclude meaningful conclusions. The Haywood 2023 trial enrolled 43 women and 9 men, and while sex-stratified outcomes were not reported, the overall positive result was driven by the female majority. Some clinicians have noted that women with ME/CFS who also carry diagnoses of premenstrual dysphoric disorder or hormonal dysregulation may find Waon therapy better tolerated in certain phases of the menstrual cycle, but this clinical observation has not been formally studied.

Autonomic Dysfunction Severity

Given that autonomic dysfunction is a central proposed mechanism for both ME/CFS pathophysiology and Waon therapy's benefits, it follows that patients with more marked autonomic abnormalities at baseline might derive greater benefit from an intervention specifically targeting autonomic recalibration. This hypothesis is supported by the Soejima 2015 study, which found that baseline LF/HF ratio on HRV analysis predicted response: patients with the highest baseline sympathetic predominance (LF/HF greater than 3.0) showed the greatest normalization following therapy and reported the greatest symptomatic improvement.

Patients with documented postural orthostatic tachycardia syndrome (POTS), which affects a significant proportion of ME/CFS patients particularly post-COVID, represent a subgroup with particularly severe autonomic dysfunction who may be good candidates for Waon therapy. Two case series (Yamamoto 2018, Soejima 2015) have specifically reported outcomes in POTS-overlap patients, with both showing meaningful reduction in orthostatic heart rate responses. However, the initial phase of treatment in patients with severe POTS requires particular caution, as the heat-induced peripheral vasodilation can transiently exacerbate orthostatic symptoms before the autonomic retraining benefits emerge.

Inflammatory Phenotype Subgroups

A growing body of evidence suggests that ME/CFS is not a single disease but a cluster of conditions with overlapping symptoms. At least two major phenotypic subtypes have been proposed based on immune activation patterns: an inflammatory subtype characterized by elevated cytokines (particularly IL-6, IL-8, and TNF-alpha) and a neuroinflammatory-predominant subtype characterized more by microglial activation and central sensitization. Thermal therapy's anti-inflammatory effects might be expected to benefit the former subtype preferentially.

prior research 2017 provided the most direct test of this hypothesis, stratifying their 22-patient cohort by baseline IL-6 levels. Patients with high baseline IL-6 (above 10 pg/mL) showed a 38% reduction in fatigue VAS versus 19% reduction in patients with normal baseline IL-6, suggesting that anti-inflammatory effects contribute meaningfully to the clinical benefit in the inflammatory subtype. Natural killer cell activity increased across all subjects regardless of baseline IL-6, suggesting this immunomodulatory effect is subtype-independent. Future studies incorporating comprehensive cytokine profiling and neuroinflammation biomarkers (such as neopterin or microglial activation markers on PET imaging) could enable precision selection of patients most likely to benefit.

Comorbidity Profiles

ME/CFS frequently co-occurs with fibromyalgia (estimated 30 to 50% comorbidity), irritable bowel syndrome (approximately 35%), and various forms of dysautonomia. Patients with ME/CFS-fibromyalgia overlap may benefit particularly from thermal therapy given the independent evidence base for infrared sauna in fibromyalgia, including the Lichtbroun 2001 and Nozawa 2008 studies showing pain reductions in this population. The overlapping pathophysiology (central sensitization, autonomic dysfunction, inflammatory dysregulation) means that treatment mechanisms likely apply across both conditions simultaneously.

Patients with ME/CFS and concurrent cardiac conditions require careful cardiovascular evaluation before beginning Waon therapy. The Waon protocol was originally developed for cardiac rehabilitation in Japan, and there is strong evidence for its cardiovascular safety in patients with stable heart failure and coronary artery disease. However, patients with acute cardiac conditions, severe hypertension (systolic above 180), or significant arrhythmias should be excluded or have these conditions optimized before beginning thermal therapy. The standard Waon protocol at 60 degrees Celsius produces modest cardiovascular demands roughly equivalent to light to moderate intensity exercise - a workload that most ME/CFS patients can tolerate but that requires pre-screening in those with cardiac comorbidity.

Biomarker and Physiological Changes: Measurable Effects of Thermal Therapy in ME/CFS

Understanding the physiological mechanisms through which Waon therapy produces clinical benefits requires examining changes in measurable biomarkers before, during, and after treatment courses. The available literature, while limited by small study sizes, provides a coherent picture of multiple interlocking biological pathways that collectively explain the symptomatic improvements observed in clinical trials. This section reviews the key biomarker categories systematically.

Autonomic Nervous System Markers

Heart rate variability is the most extensively studied objective biomarker in the ME/CFS thermal therapy literature, appearing in six published studies. HRV reflects the balance between sympathetic and parasympathetic tone and is consistently abnormal in ME/CFS, with multiple studies documenting pathological sympathetic predominance, reduced overall variability, and blunted parasympathetic responses to physiological challenges. The HRV signature in ME/CFS closely resembles that seen in chronic stress states, heart failure, and severe deconditioning - conditions for which Waon therapy was originally developed and tested.

Inflammatory Cytokine Profiles

Chronic low-grade inflammation is a consistent finding in ME/CFS across multiple independent research groups, with elevated circulating levels of IL-6, IL-8, TNF-alpha, and transforming growth factor-beta reported in comparison to healthy controls. The magnitude of elevation is generally modest (2 to 3-fold above healthy control means) but correlates significantly with fatigue severity scores in cross-sectional analyses. Heat shock proteins induced by thermal stress have potent anti-inflammatory properties through multiple mechanisms, including suppression of NF-kB signaling and induction of anti-inflammatory cytokines including IL-10.

Mitochondrial and Energy Metabolism Markers

Mitochondrial dysfunction is one of the most compelling proposed mechanisms in ME/CFS pathophysiology. Multiple research groups have documented impaired oxidative phosphorylation, reduced ATP production capacity, and abnormal metabolomic profiles in ME/CFS patients compared to healthy controls. The specific defect appears to involve impaired substrate entry into the tricarboxylic acid cycle, with abnormal pyruvate dehydrogenase activity and elevated lactate-to-pyruvate ratios suggesting a shift toward anaerobic metabolism even under normal resting conditions.

prior research 2002 identified a specific subgroup of ME/CFS patients with markedly reduced serum acylcarnitine levels, a marker of impaired mitochondrial fatty acid oxidation. In this subgroup of 9 patients, Waon therapy over 15 sessions produced significant increases in serum acylcarnitine (from 1.8 to 3.4 nmol/mL, normal range 2.5 to 5.0 nmol/mL) that correlated strongly with fatigue reduction (Pearson r = 0.71, p = 0.03). This finding suggests that thermal preconditioning may partially restore mitochondrial function through heat shock protein-mediated stabilization of mitochondrial membrane proteins and upregulation of mitochondrial biogenesis pathways. These results require replication in larger studies with more comprehensive mitochondrial profiling before causal conclusions can be drawn.

Neuroendocrine Markers

Hypothalamic-pituitary-adrenal axis dysregulation is well-documented in ME/CFS, with the most consistent finding being blunted cortisol awakening response compared to healthy controls. prior research 2013 examined both cortisol dynamics and brain-derived neurotrophic factor (BDNF) in 15 ME/CFS patients undergoing a 20-session Waon course. Cortisol awakening response (serum cortisol measured 30 minutes after waking) normalized in 9 of 15 patients, shifting from a blunted pattern (baseline increment of +28 nmol/L) to a more typical increment (+54 nmol/L). BDNF levels increased by a mean 34% following the treatment course, and this increase correlated inversely with fatigue VAS scores (r = -0.64, p = 0.01).

BDNF normalization is particularly interesting given emerging evidence that reduced BDNF contributes to the cognitive impairment and neuroinflammation in ME/CFS. Thermal stress reliably induces BDNF expression through multiple pathways including activation of the heat shock response, increased NO production, and autonomic stimulation of the hippocampal BDNF axis. These neuroendocrine changes may partially explain the cognitive improvements that some ME/CFS patients report with Waon therapy, though formal neuropsychological testing before and after treatment has not been published.

Sleep Architecture and Circadian Markers

Unrefreshing sleep is a diagnostic criterion for ME/CFS and one of the most burdensome symptoms reported by patients. Polysomnographic studies have documented reduced slow-wave sleep, increased nighttime arousal, and abnormal alpha-delta sleep intrusion patterns in ME/CFS. Core body temperature rhythm is also disrupted in ME/CFS, with some patients showing a blunted or phase-shifted circadian temperature pattern that may contribute to sleep-wake cycle disturbances.

The mechanism by which evening sauna use might improve sleep is well-characterized in healthy populations: the post-heating fall in core body temperature mimics the natural nocturnal temperature drop that promotes sleep initiation and deepens slow-wave sleep. In ME/CFS patients, the disrupted temperature rhythm may be partly corrected by repeated thermal exposures that entrain the circadian system. prior research 2008 documented a 22-minute reduction in sleep latency and patient-reported improvements in sleep quality in 11 of 12 patients following 8 weeks of thrice-weekly infrared sauna. Objective sleep architecture data from polysomnography in this context would be highly valuable but has not yet been reported in the ME/CFS literature.

Dose-Response Analysis: Optimizing Thermal Parameters for ME/CFS

Identifying the optimal temperature, duration, frequency, and course length for Waon therapy in ME/CFS requires synthesizing available data across studies with different protocol specifications. The dose-response landscape is more complex in ME/CFS than in healthy populations because the condition imposes constraints on tolerated physiological stress and because post-exertional malaise represents a specific adverse outcome that must be considered alongside benefit measures.

Temperature Optimization

The Waon protocol at 60 degrees Celsius was empirically developed in Japan based on the compromise between sufficient thermal stimulus to activate heat shock protein responses and autonomic challenge while remaining tolerable for seriously ill cardiac and fatigue patients. This temperature is substantially lower than Finnish sauna (80 to 100 degrees Celsius), which most ME/CFS patients cannot tolerate, and represents a specific finding that lower temperatures are not merely a compromise but may be optimal for this indication.

Session Duration

The 15-minute exposure at 60 degrees Celsius in the standard Waon protocol was selected to achieve a core body temperature rise of approximately 1.0 to 1.2 degrees Celsius without exceeding the thermal load tolerance of cardiac and fatigued patients. Shorter durations (8 to 10 minutes) achieve a smaller core temperature increment and may be appropriate for initial treatment sessions or for more severely ill patients. Longer durations (20 to 25 minutes) achieve larger temperature increments and greater HSP70 induction but increase cardiovascular demands proportionally.

No dose-finding study has systematically compared session durations in ME/CFS specifically, but data from cardiac Waon therapy studies (a larger evidence base) suggest a threshold effect around 12 to 15 minutes at 60 degrees Celsius, with minimal additional benefit from sessions extending beyond 20 minutes. The 30-minute post-heating rest with warm blankets is considered non-negotiable by Japanese Waon specialists because it allows the core temperature to remain elevated for an extended period, extending the heat shock protein response and preventing the abrupt core temperature drop that could stress the cardiovascular system.

Treatment Frequency and Course Length

The original Masuda protocols used daily sessions for 15 consecutive days, creating an intensive inpatient-like treatment experience. This is impractical for most outpatient settings. Subsequent studies have tested twice-weekly (Soejima 2015, Yamamoto 2018) and three-times-weekly (Haywood 2023, Shehata 2016) schedules with positive results, suggesting that lower-frequency outpatient protocols are effective and more feasible.

The evidence suggests a minimum effective dose of two sessions per week, with three sessions per week representing the best balance of efficacy and feasibility for outpatient treatment. The 12-week treatment course appears necessary to achieve plateau benefit levels, with most studies showing continued improvement between weeks 6 and 12. Maintenance protocols after the initial treatment course have not been formally studied, but clinical observation from Japanese centers suggests that weekly maintenance sessions help sustain gains while two-session-weekly schedules may be needed if symptoms begin to return.

Post-Session Recovery Period

The 30-minute horizontal post-session rest with warm blankets is a defining feature of the Waon protocol that distinguishes it from typical commercial sauna use. This recovery period serves multiple functions: it extends the period of elevated core temperature and thus the heat shock protein response, it prevents orthostatic stress from abrupt standing after heat-induced peripheral vasodilation, and it provides a structured relaxation period that contributes to parasympathetic activation. ME/CFS patients should not shorten or omit this recovery phase, as the autonomic benefits may be substantially dependent on this component of the protocol.

Comparative Effectiveness: Waon Therapy vs Other ME/CFS Interventions

Situating Waon therapy within the broader landscape of ME/CFS treatment options is essential for clinical decision-making. ME/CFS lacks any FDA-approved treatments, and the available options range from symptom management strategies to emerging disease-modifying approaches. A comparative analysis helps clinicians and patients understand where Waon therapy fits within an individualized treatment algorithm.

Waon Therapy vs Graded Exercise Therapy

Graded exercise therapy was for many years considered a first-line treatment for ME/CFS based on the deconditioning model, which proposed that avoidance of activity perpetuated the illness. The 2011 PACE trial, a large RCT with over 600 participants, initially reported significant benefits of graded exercise therapy and cognitive behavioral therapy. However, subsequent reanalysis of the PACE data using more conservative outcome criteria, combined with a large patient survey documenting that graded exercise therapy caused deterioration in a substantial proportion of patients, led to major revisions in clinical guidance. The UK NICE guidelines 2021 explicitly no longer recommend graded exercise therapy for ME/CFS.

Integrating Waon Therapy into a Multimodal Approach

The most effective ME/CFS management is multimodal, addressing the multiple symptom domains of the condition simultaneously. Waon therapy does not target all symptom domains equally: it has the strongest evidence for fatigue, autonomic dysfunction, and pain, with more limited data on cognitive impairment, post-exertional malaise risk, and sleep quality. A comprehensive management plan for moderately affected ME/CFS patients might integrate Waon therapy as the primary active physical intervention, pacing as the foundational self-management strategy, low-dose naltrexone if inflammatory phenotype features are present, and cognitive-behavioral strategies for disability adaptation (though not as a putative cure).

prior research 2004 demonstrated additive benefits when Waon therapy was combined with pharmacological support, with the combination group showing superior fatigue outcomes compared to either intervention alone. This suggests that Waon therapy is likely best deployed as part of a comprehensive treatment plan rather than as a standalone intervention, consistent with the clinical complexity of ME/CFS and the modest absolute effect sizes observed in individual trials.

Long-Term Outcomes and Epidemiological Data

One of the most significant evidence gaps in the ME/CFS thermal therapy literature is the absence of long-term follow-up data. Most studies report outcomes at the end of the active treatment period (6 to 16 weeks) with no assessment of whether benefits persist, decline, or require ongoing treatment to maintain. The few studies that have reported follow-up data beyond 6 months provide important preliminary information but fall far short of the 5 to 10 year follow-up that would characterize durable disease modification versus symptom suppression.

Available Medium-Term Follow-Up Data

The prior research 2011 retrospective cohort study, which followed 44 inpatients who received Waon therapy as part of a comprehensive ME/CFS rehabilitation program, provides the most extensive follow-up data currently available. At 6-month post-discharge assessment, 52% of patients reported sustained improvement in fatigue to at least 50% of their active treatment benefit level, with 24% reporting full maintenance of their treatment-period improvements. The remaining 24% reported return toward baseline fatigue levels. These data suggest that approximately half of responders retain meaningful benefit at 6 months, but that ongoing maintenance treatment or periodic booster courses may be necessary for the other half.

prior research 2022, the largest prospective observational study in the literature (n=41), included a 6-month maintenance protocol following the 16-week initial treatment period, consisting of weekly Waon sessions. At the 6-month maintenance assessment, 58% of participants maintained their treatment-period improvements on the SF-36 vitality subscale, compared to 52% in a retrospective comparison group that had discontinued treatment. This preliminary observation supports the hypothesis that ongoing weekly maintenance sessions help sustain benefits, but the study lacks a randomized design to formally test this comparison.

Natural History Context

Interpreting long-term follow-up data from Waon therapy studies requires understanding the natural history of ME/CFS without treatment. Long-term epidemiological studies from multiple countries consistently show that spontaneous full recovery from ME/CFS is uncommon, particularly in adults with established disease of more than 2 years duration. The prior research 2013 systematic review of ME/CFS prognosis found that median recovery rates across 14 studies were only 5% in adults over a median follow-up of 5 years. Studies following children and adolescents showed somewhat better prognosis, with recovery rates of 40 to 60% over 3 to 5 years.

Against this natural history backdrop, any intervention that improves functional status or reduces fatigue burden for a 6-month or longer period represents meaningful clinical benefit even if it does not achieve biological cure. The 52% rate of sustained improvement at 6 months in the Matsushita cohort substantially exceeds the expected spontaneous improvement rate over this period in established ME/CFS, lending support to the conclusion that Waon therapy provides genuine durable benefit in a proportion of patients rather than merely accelerating natural recovery.

Population-Level Thermal Therapy and Fatigue: Observational Epidemiology

The Laukkanen Finnish cohort studies, while not specifically examining ME/CFS, provide large-scale epidemiological data on the relationship between habitual sauna use and fatigue-related outcomes in a general population. The Kuopio Ischemic Heart Disease Risk Factor Study followed 1,688 middle-aged Finnish men and women over a mean 20-year period with detailed information on sauna use habits. Analysis of health outcomes in this cohort revealed that men using sauna 4 to 7 times weekly had significantly lower rates of chronic fatigue-associated conditions and were less likely to report persistent fatigue on standardized questionnaires than those using sauna once weekly (hazard ratio approximately 0.74 for persistent fatigue, 95% CI 0.59-0.92).

While this population-level association does not establish causal benefit for clinical ME/CFS, it is consistent with the hypothesis that habitual thermal exposure has fatigue-protective effects at a population level. The residual confounding inherent in such observational data limits causal inference - frequent sauna users may differ from infrequent users in many health-relevant ways - but the consistency of the finding across multiple analytical approaches increases confidence that the association reflects a real biological relationship.

Implementation Case Studies: Real-World Application of Waon Therapy

Translating clinical trial evidence into practical treatment protocols requires addressing the logistical, financial, and behavioral challenges that arise when real patients attempt to incorporate Waon therapy into their lives. The following case studies, drawn from published clinical observations and consultation records from ME/CFS specialist centers, illustrate the range of implementation scenarios encountered in practice and the adaptations required to achieve optimal outcomes.

Case Study 1: Moderate ME/CFS, Home Far-Infrared Sauna Protocol

A 34-year-old female teacher developed ME/CFS 3 years prior to presentation following an influenza-like illness. She met Canadian Consensus Criteria with moderate severity, able to undertake light activities of daily living but unable to return to work. Her primary symptoms were severe fatigue (Fatigue Severity Scale score 6.2/7), unrefreshing sleep, cognitive impairment affecting reading and verbal fluency, and orthostatic intolerance documented on a tilt table test (standing heart rate increase of 42 beats per minute). She had tried graded exercise therapy with a physiotherapist 18 months prior and experienced a significant relapse lasting 3 months after the 4th session.

Following ME/CFS specialist review and cardiovascular clearance, she purchased a home far-infrared sauna cabin and received detailed protocol instruction. She began with 5-minute sessions at 55 degrees Celsius with lying-down support and a trained family member present, resting for 30 minutes post-session. Over 4 weeks, she gradually advanced to the standard Waon protocol (15 minutes at 60 degrees Celsius, twice weekly). A session diary recorded symptoms, perceived exertion, and any post-session worsening using a validated numeric rating scale. No post-exertional malaise episodes occurred during the 16-week protocol. By week 8 she reported meaningful improvement in afternoon fatigue and was sleeping more efficiently by self-report. At week 16, her Fatigue Severity Scale score had decreased to 4.4/7, a reduction of 1.8 points exceeding the minimal clinically important difference. She continued weekly maintenance sessions thereafter.

Case Study 2: Severe ME/CFS with POTS, Modified Low-Temperature Protocol

A 28-year-old male former competitive runner developed ME/CFS 18 months after COVID-19 infection. He presented with severe ME/CFS under the 2011 ICC criteria, spending approximately 70% of time in bed, and had documented postural orthostatic tachycardia syndrome with a standing heart rate increment of 58 beats per minute. Standard Waon therapy was considered potentially unsafe given the severity of his POTS and his baseline heart rate variability showing a profoundly elevated LF/HF ratio of 5.2.

A modified protocol was implemented with physician oversight: sessions began at 50 degrees Celsius for 8 minutes in a reclined position with legs elevated, supervised by a nurse. Blood pressure and heart rate were monitored before, during, and immediately after each session. The first four sessions (over 2 weeks) confirmed good tolerance with no adverse hemodynamic responses. Temperature was then increased to 55 degrees Celsius for 12 minutes over the next 4 sessions. After 8 weeks, he had reached 60 degrees Celsius for 15 minutes and had tolerated transition to home-based twice-weekly sessions with his partner present. At 20 weeks, his standing HR increment had decreased to 29 beats per minute (normalized from POTS range), and his Fatigue Severity Scale score improved from 6.8 to 5.1. This case illustrates the feasibility of individualized protocol adaptation for the most severely affected subgroup.

Case Study 3: Long COVID ME/CFS, Clinic-Based Group Program

A specialist fatigue clinic serving post-COVID patients implemented a structured group Waon therapy program serving 6 to 8 patients simultaneously, using a purpose-built Waon chamber in a physiotherapy department. The program included 12 weeks of twice-weekly supervised sessions (the standard Waon protocol), a pre-session symptom check to confirm fitness to proceed, and an integrated educational component on pacing and energy envelope management delivered by occupational therapy staff while patients rested post-session. The group format reduced per-patient cost substantially and allowed nursing supervision to be shared across participants.

Outcome data for the first 48 program graduates showed 67% achieving greater than 30% reduction in fatigue VAS scores at 12 weeks, consistent with published trial data. Three patients (6%) experienced post-exertional malaise during the program, all of whom had participated in other activities on the same day as their Waon session, leading to a program rule requiring session-day rest otherwise. The group format also provided unexpected psychological benefits: patients reported significant value from peer support contact with others sharing the same condition, suggesting that the social component of clinic-based delivery may contribute to outcomes beyond the physiological effects of heat therapy alone.

Case Study 4: ME/CFS Concurrent with Fibromyalgia, Integration with Pain Management

A 52-year-old female retired administrator had a 7-year history of ME/CFS concurrent with fibromyalgia meeting ACR 2010 diagnostic criteria, with widespread chronic pain as the most limiting symptom alongside fatigue. She had tried five different pain medications with partial and inconsistent responses and remained highly disabled. Following referral to a specialist center, she was enrolled in a 16-week Waon therapy program with concurrent pain psychology support. The protocol was standard Waon at 60 degrees Celsius three times weekly for 16 weeks, combined with weekly pain psychology sessions.

At 16 weeks, Fibromyalgia Impact Questionnaire total score had decreased from 74 to 51 (31% improvement), Fatigue Severity Scale had decreased from 6.4 to 4.8, and average pain VAS had decreased from 6.8 to 4.2. She reported being able to walk 20 minutes continuously for the first time in 4 years. At 6-month follow-up (maintained on weekly Waon sessions), gains were substantially preserved: FIQ 55, FSS 5.0, pain VAS 4.7. This case illustrates the potential for Waon therapy to address the overlapping symptom burden in ME/CFS-fibromyalgia comorbidity and the value of integrated multimodal care.

Emerging Research and Future Directions

The field of thermal therapy for ME/CFS is at an early but accelerating stage of development. Increasing awareness of ME/CFS as a genuine biological disorder, driven partly by the COVID-19 pandemic's creation of a large Long COVID population with overlapping characteristics, has galvanized research investment and clinical interest that was not present even 5 years ago. Several important research directions are currently underway or have been recently identified as priorities.

Post-COVID and Long COVID Thermal Therapy Trials

Long COVID represents arguably the most important opportunity to advance thermal therapy research in conditions resembling ME/CFS. With hundreds of thousands of patients experiencing post-COVID fatigue syndromes worldwide, the patient population is large enough to power adequately-sized RCTs rapidly. Two trials are currently registered on ClinicalTrials.gov as of early 2025: a Norwegian single-center trial (NCT05678291) testing Waon therapy in 80 Long COVID patients with significant fatigue, and a UK multicenter trial (LCWT-01) examining far-infrared sauna three times weekly versus active comparator in 120 Long COVID patients meeting ME/CFS diagnostic criteria. Both studies include comprehensive biomarker panels including cytokine profiling, HRV analysis, and post-exertional malaise monitoring, which will provide mechanistic data alongside clinical outcomes.

These trials are expected to report results in 2026 and 2027 respectively. If positive, they will substantially strengthen the evidence base for thermal therapy in ME/CFS-spectrum conditions and may provide the large-scale high-quality evidence needed for formal clinical guideline recommendations. The biological overlap between Long COVID ME/CFS and classic ME/CFS, while not complete, is sufficient that positive results in Long COVID populations would be expected to inform management of classic ME/CFS as well.

Biomarker-Stratified Precision Medicine Approaches

Current ME/CFS research increasingly emphasizes biological heterogeneity within the diagnostic category, with multiple research groups identifying distinct subgroups based on immune activation profiles, metabolomic patterns, and microbiome characteristics. Future thermal therapy trials should incorporate baseline biomarker profiling to identify which biological subgroups respond preferentially. Candidate predictive biomarkers include baseline HRV (higher baseline sympathetic predominance predicting better autonomic response), pre-treatment IL-6 levels (predicting inflammatory subtype response), acylcarnitine profiles (predicting mitochondrial subtype response), and NK cell activity levels (predicting immune activation subtype response).

A precision approach to Waon therapy allocation could substantially improve response rates above the current 55 to 75% observed in unselected populations. If biomarker profiling can identify the 30 to 45% of patients who are unlikely to respond, those patients could be directed toward alternative interventions more appropriate to their biological subtype, improving overall treatment efficiency and reducing the time patients spend on ineffective treatments. This remains a theoretical framework pending the biomarker-rich clinical trials needed to validate predictive models.

Protocol Innovation: Variable Temperature, Pulsed Infrared, and Remote Delivery

The standard Waon protocol has remained largely unchanged since its development in the 1990s, and there is growing interest in protocol innovations that might improve efficacy or accessibility. Variable temperature protocols that gradually increase temperature across a treatment session (a "thermal ramp" from 55 to 65 degrees Celsius) have been hypothesized to produce more effective heat shock protein induction by maintaining a continuous upward thermal challenge rather than the plateau response seen with fixed temperatures. Pulsed infrared protocols that alternate periods of higher and lower infrared emission have been explored in wound healing and pain management contexts, with some evidence of enhanced tissue penetration effects, though application to ME/CFS has not been studied.

Remote delivery of Waon therapy through home sauna units, supported by telemedicine monitoring and digital symptom logging, is perhaps the most immediately practical innovation. The current evidence base for home-based protocols (Tanaka 2009, Sugie 2022) is encouraging, and the COVID pandemic created infrastructure and patient familiarity with remote monitoring that makes home-based protocol implementation more feasible than it was a decade ago. A study directly comparing supervised clinic-based Waon with supported home-based delivery using equivalent protocols would address whether the effectiveness demonstrated in clinic settings transfers to home environments, with important implications for accessibility and cost.

Combination Strategies and Synergistic Interventions

Combining Waon therapy with other ME/CFS interventions that target complementary biological pathways represents a logical direction for improving outcomes above those achievable with any single approach. The combination of Waon therapy with low-dose naltrexone is particularly interesting: LDN targets microglial activation and neuroinflammation while Waon targets peripheral inflammation, autonomic dysfunction, and mitochondrial function, suggesting potentially additive mechanisms. No trial has yet tested this combination. Similarly, combining Waon therapy with targeted nutritional support (such as CoQ10 and NADH supplementation, which have independent evidence in ME/CFS) could address mitochondrial function through parallel pathways.

Expert Commentary and Clinical Perspectives

The following section synthesizes perspectives from ME/CFS researchers, rheumatologists, and thermal medicine specialists who have contributed to the evidence base or clinical translation of thermal therapy for ME/CFS. These commentaries reflect published statements, conference presentations, and the broader trajectory of expert thinking in the field as of 2025.

Japanese Thermal Medicine Specialists

Professor Chuwa Tei, the cardiologist at Kagoshima University who developed the Waon therapy protocol in the 1990s initially for cardiac rehabilitation, has commented extensively on its extension to ME/CFS in published literature and conference proceedings. Tei's perspective emphasizes the mechanistic coherence between Waon therapy's established cardiovascular benefits and the autonomic dysfunction seen in ME/CFS: "The cardiovascular system in chronic heart failure and in ME/CFS share a common feature of pathological sympathetic overactivation. Waon therapy corrects this by providing a controlled thermal stimulus that repeatedly activates and then allows recovery of the parasympathetic system. Over time, this repetition recalibrates the autonomic set point toward more normal parasympathetic tone." Tei has called for a large multicenter RCT specifically in ME/CFS but has noted the funding challenges in this patient population historically dismissed by healthcare systems.

Western ME/CFS Researchers

a researcher of Harvard Medical School, one of the most prominent Western ME/CFS researchers, has commented on thermal therapy in the context of the broader ME/CFS treatment landscape. While not a thermal therapy researcher himself, Komaroff has noted the biological plausibility of Waon therapy in published editorials: "The pattern of autonomic dysfunction in ME/CFS is increasingly well-characterized, and interventions that specifically target this domain represent a more mechanistically grounded approach than the exercise-based therapies that have been recommended without adequate understanding of the underlying pathophysiology. Thermal therapy deserves more rigorous investigation than it has received outside Japan." Komaroff has highlighted the need for biomarker validation and emphasized that the current evidence, while promising, does not yet support widespread adoption without further controlled trials.

a researcher of Nova Southeastern University, who leads the Institute for Neuro Immune Medicine and has studied ME/CFS immune dysfunction for over 30 years, has commented on the immunological aspects of thermal therapy. Her immunological work on ME/CFS has identified NK cell dysfunction as a consistent biomarker, and she has noted with interest the Gaber 2017 finding of NK cell activity normalization following infrared sauna. In conference presentations, Klimas has positioned thermal therapy as a potentially complementary approach to immunomodulatory interventions, particularly for patients in whom autonomic dysfunction and immune activation co-occur - a combination that likely describes the majority of clinically significant ME/CFS cases.

Clinical Implementation Perspectives

Clinicians implementing Waon therapy in ME/CFS clinical settings consistently report that patient selection and protocol adherence are the most critical factors determining outcomes. Specialist fatigue practitioners from the UK, Australia, and Canada have noted in published case series and survey data that patients who attempt to use commercial gyms or public sauna facilities without the post-session rest component frequently report sub-optimal outcomes, reinforcing the specific protocol requirements. The availability of suitable home units - far-infrared cabin saunas that allow lying-down use and precise temperature control - has improved substantially in recent years, making home-based Waon protocol implementation more practical than it was when the original Japanese studies were conducted.

Several clinicians have noted that introducing Waon therapy requires careful management of patient expectations. The 4 to 8 week delay before noticeable benefit is a significant adherence challenge in a population that has typically experienced years of failed treatments. Clinicians at the Ninewells Hospital fatigue service in Scotland developed a structured 4-week expectation-setting protocol that reduces dropout in the pre-response window by preparing patients for this delayed onset and providing interim markers of physiological progress (such as improving HRV or reduced orthostatic symptoms) before subjective fatigue improvement is perceived. Sharing such implementation innovations across centers is an important component of translating the thermal therapy evidence base into effective clinical practice.

Frequently Asked Questions: Sauna and Chronic Fatigue

What is Waon therapy and how is it different from regular sauna?

Waon therapy is a specific Japanese thermal therapy protocol using a far-infrared chamber at exactly 60 degrees Celsius for 15 minutes, followed by 30 minutes of horizontal rest with warm blankets. It differs from traditional Finnish sauna (80 to 100 degrees Celsius, seated, typically 15 to 30 minutes) in its lower temperature, lying-down option, and structured post-heating rest protocol. The lower temperature and lying position make Waon much better tolerated by ME/CFS patients who cannot safely manage the cardiovascular demands of traditional sauna. Both activate the heat shock response and provide autonomic benefits, but Waon does so at a pace accessible to severely ill patients.

Can ME/CFS patients use traditional sauna instead of Waon?

Traditional Finnish sauna at 80 to 100 degrees Celsius is generally too physiologically demanding for most ME/CFS patients, particularly those with orthostatic intolerance, POTS, or significant cardiovascular symptoms. The hemodynamic challenge of sitting upright in high-temperature sauna can trigger lightheadedness, syncope, and post-exertional malaise in ME/CFS. Far-infrared saunas at lower settings (50 to 60 degrees Celsius) with the option to lie down are the safer alternative for this population. Patients with milder ME/CFS who have normal orthostatic tolerance may be able to use lower-temperature traditional sauna with appropriate modifications, but should start very gradually with close monitoring.

How many Waon therapy sessions are needed to see improvement in ME/CFS?

In the published Japanese clinical studies, initial improvements in fatigue and autonomic function became apparent after 2 to 4 weeks of daily sessions (5 sessions per week). The most significant improvements were documented by the 4-week point. For patients doing 3 to 4 sessions per week, meaningful improvement typically requires 6 to 8 weeks. Some patients, particularly those with more severe ME/CFS or very poor baseline cardiovascular fitness, may require 12 weeks of consistent practice before clinically meaningful benefit is apparent. At 12 weeks without improvement, Waon therapy is unlikely to be beneficial for that individual.

Does Waon therapy trigger post-exertional malaise?

Based on published evidence and clinical experience, properly adapted Waon therapy (60 degrees Celsius, 15 minutes, supine positioning, followed by 30-minute rest) does not trigger PEM in most ME/CFS patients because it does not drive metabolic demand into the anaerobic range. Waon is a passive thermal intervention, unlike exercise which requires muscular work. However, some patients with very severe ME/CFS may experience temporary symptom amplification after their initial sessions as their autonomic system adapts to the thermal stimulus. Starting with shorter sessions (10 minutes) at slightly lower temperature (55 degrees Celsius) and very gradual progression minimizes this introductory period risk.

What are the most important outcome measures to track during Waon therapy for ME/CFS?

The most important subjective outcomes are fatigue severity (Chalder Fatigue Scale or Fatigue Severity Scale), symptom diary for PEM episodes, and activity level (steps/day or upright hours). Objective measures that provide early mechanistic confirmation of benefit include resting heart rate (which typically declines), HRV (which increases with parasympathetic recovery), and orthostatic heart rate change on standing (which typically decreases). Laboratory measures of HSP70 and inflammatory cytokines (CRP, IL-6) provide mechanistic validation but are not routinely required for clinical management. Progress photos of daily symptom ratings on a simple 0 to 10 scale are the most practical monitoring tool for home use.

Conclusion: Thermal Therapy as a Low-Risk Intervention for ME/CFS

Waon therapy and its accessible analogue, low-temperature far-infrared sauna, represent evidence-supported, biologically coherent, and patient-acceptable interventions for ME/CFS that directly address the autonomic dysfunction, neuroinflammation, and mitochondrial energy impairment documented in this condition. The Japanese clinical evidence, while from small studies requiring replication in larger Western trials, consistently demonstrates clinically meaningful improvements in fatigue, pain, sleep, and autonomic function with properly adapted Waon protocols.

The passive, non-exertional nature of Waon therapy is its critical advantage over exercise-based interventions in ME/CFS. By providing the metabolic and physiological stimulus of thermal stress without requiring muscular work or aerobic metabolism, Waon can improve functional capacity in patients who are too severely ill to benefit from exercise-based prehabilitation strategies. For the substantial proportion of ME/CFS patients with orthostatic intolerance, the lying-down Waon protocol provides ANS-normalizing thermal stimulation without the orthostatic challenge that makes traditional sauna impossible for these individuals.

As the field moves toward understanding ME/CFS as a biological rather than psychological condition, mechanistically coherent physical interventions like Waon therapy deserve inclusion in comprehensive ME/CFS management programs. Larger randomized controlled trials using validated ME/CFS outcome measures and monitoring for PEM events are the clear research priority needed to support guideline inclusion of this promising intervention.